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Abstract 
ABSTRACT 
Thyroid hormones (TH) play an essential role both in the developing and the adult central 
nervous system (CNS). The concentrations of the genomically active hormone T3 in the brain 
depend on TH transport across the brain barriers, the local generation of T3 in astrocytes by 
type 2 deiodinase (D2), and TH degradation by type 3 deiodinase (D3). In addition, during 
foetal development, circulating TH concentrations derive partly from the mother. How all 
these factors interact during mice foetal development to ensure “brain euthyroidism” is not 
well known. 
This work has explored the sources of T3 that ensure brain euthyroidism during mice foetal 
development by treating euthyroid pregnant dams with T4 or T3 from embryonic day 12 (E12) 
to E18. The outcome of the treatment revealed that a large amount of foetal T4 during late 
gestation is of maternal origin and that maternal-foetal T3 transfer is tightly regulated, most 
probably at the placental level. Also, that T4 transport across the choroid plexus along with D2 
activity at the blood-cerebrospinal fluid barrier might be key events in TH action in brain 
during foetal development, as conversion of T4 into T3 by D2 activity might be the only 
source of T3 during mouse brain development. 
Mutations in the gene expressing the TH monocarboxylate transporter 8 (MCT8), in humans, 
lead to altered circulating TH levels and a severe neurodevelopmental disorder. Due to the 
crucial role of this transporter, the  interaction between Mct8-dependent transport and D2 
activity was studied. D2 activity was found to be required to generate the brain 
hyperthyroidism characteristic of Mct8 deficient (Mct8KO) animals during perinatal stages of 
development.  
Besides, Mct8KO mice were used to test novel therapeutic approaches as possible treatments 
for MCT8 deficiency. The use of the TH analogue  triiodothyroacetic acid (TRIAC) restored 
plasma T3 levels but severely decreased T4 levels leading to a state of brain hypothyroidism 
with reduced T3 content. Delivery of MCT8 by adeno-associated virus vectors proved that, for 
a successful gene therapy, restoration of MCT8 at the brain barriers is critical to mediate TH 
access to the brain of MCT8 deficient patients. Finally, intranasal delivery of TH as an 
alternative administration route increased TH levels in the systemic circulation, aggravating 
the peripheral hyperthyroidism, suggesting that is not a treatment option for MCT8 deficient 
patients.
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Resumen 
RESUMEN 
Las hormonas tiroideas (HT) juegan un papel esencial en el desarrollo y función del sistema 
nervioso central. En el cerebro, las concentraciones de la hormona activa a nivel genómico, T3, 
dependen del transporte de HT a través de las barrera cerebrales, de la generación local de T3 
en los astrocitos mediante la desyodasa tipo 2 (D2) y de la degradación de HT por la desyodasa 
tipo 3 (D3). Además, durante el desarrollo fetal las concentraciones de HT circulantes 
provienen en parte de la madre. Cómo interactúan todos estos factores durante el desarrollo 
fetal en ratón para asegurar un “eutiroidismo cerebral” no se conoce suficientemente. 
En este trabajo se han explorado las fuentes de T3 que posibilitan un eutiroidismo cerebral 
durante el desarrollo fetal del ratón mediante el tratamiento de madres gestantes con T4 o T3 
desde el día embrionario 12 (E12) hasta E18. El resultado del tratamiento reveló que una gran 
parte de la T4 fetal durante las fases finales de la gestación es de origen materno y que la 
transferencia materno-fetal de T3 está estrictamente regulada, probablemente a nivel 
placentario. También, que el transporte de T4 a través del plexo coroideo junto con la actividad 
de D2 en la barrera sangre-líquido cefalorraquídeo podrían ser eventos claves en la acción de 
las HT en el cerebro durante el desarrollo fetal, ya que la conversión de T4 a T3 mediante la 
actividad de D2 podría ser la única fuente de T3 durante el desarrollo cerebral del ratón. 
Mutaciones en el gen que expresa el transportador de HT, transportador de monocarboxilatos 8  
(MCT8), provocan alteraciones en los niveles circulantes de HT y discapacidades graves del 
neurodesarrollo en humanos. Debido al papel fundamental de este transportador, se estudió la 
interacción entre el transporte dependiente de Mct8 y la actividad de D2. Los resultados 
indican que la actividad de D2 es necesaria para generar el hipertiroidismo cerebral 
característico de los ratones deficientes de Mct8 durante etapas perinatales del desarrollo. 
Además, se utilizaron ratones deficientes de Mct8 para examinar nuevas aproximaciones 
terapéuticas como posibles tratamientos para la deficiencia de MCT8. El uso del análogo de 
HT ácido triyodotiroacético (TRIAC) restableció los niveles plasmáticos de T3 pero redujo 
drásticamente los niveles de T4 generando un estado de hipotiroidismo cerebral con bajo 
contenido de T3. La administración de MCT8 mediante virus adeno-asociados demostró que, 
para una eficaz terapia génica, es crítico reestablecer MCT8 en las barreras cerebrales  para 
mediar el acceso de HT en el cerebro de pacientes deficientes de MCT8. Finalmente, la 
administración de HT por vía intranasal como vía alternativa aumentó los niveles circulantes 
de HT agravando el hipertiroidismo periférico lo que sugiere que no es una opción para el 
tratamiento de pacientes deficientes de MCT8. 
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Introduction 
1. Thyroid Hormones 
Thyroid hormones (TH) are essential for the correct development of vertebrates controlling 
cell growth and metabolism in all tissues. The developing central nervous system (CNS) is 
particularly sensitive to TH deficiency as TH deficit leads to numerous alterations. The 
severity of these alterations depends on the timing of this deficit. While the wide range of 
clinical manifestations of adult onset hypothyroidism are usually reversed with an appropriate 
treatment, TH deficit during prenatal development can lead to irreversible neurological 
alterations unless treated with a timely hormonal replacement therapy (Morreale de Escobar et 
al., 2000) highlighting the importance of both appropriate levels of TH and timing of action. 
 
1.1  Synthesis, secretion and tissue distribution 
TH are iodinated amino acids synthesised in the thyroid gland. Of the total hormonal secretion 
of the thyroid gland about 93% is as  the  prohormone thyroxine or 3,5,3’,5’-tetraiodo-L-
thyronine (T4) and  7% as 3,5,3’-triodo-L-thyronine (T3), the active form at the genomic level 
(Braverman and Utiger, 2000). The synthesis and secretion of TH are controlled by the 
hypothalamus-pituitary-thyroid axis. In the paraventricular nucleus (PVN) of the hypothalamus 
the thyrotropin-releasing hormone (TRH) is synthesised and secreted, which in turn stimulates 
the pituitary gland inducing the secretion of thyroid-stimulating hormone (TSH). TSH binds to 
its G-protein-coupled receptor in the thyroid gland and stimulates the biosynthesis of TH and 
secretion into the plasma. Both TRH and TSH are negatively regulated by TH (Chiamolera and 
Wondisford, 2009). 
Most of the TH in the blood circulate bound to the transport proteins thyroxine binding 
globulin (TBG), transthyretin (TTR) and albumin (human serum albumin, HSA). Taking into 
account their molar concentrations as well as the association constants for T4, TBG binds 75% 
of serum T4, while TTR and HSA only bind 20% and 5%, respectively. In the serum 
approximately 0.03% of the total T4 and 0.3% of the total T3 are present in free or unbound 
form (Refetoff, 2015). The bound T4 is in rapid equilibrium with free T4 (FT4) that is 
available for cellular uptake. TH binding proteins allow T4 distribution through circulation and 
increase its half-life in blood serum (Schussler, 2000). 
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1.2 Metabolism 
TH metabolic pathways include deiodination, sulfation, glucuronidation and oxidative 
deamination. Among these, sequential deiodination is the most important. Iodothyronine 
deiodinases are selenoproteins that catalyse the removal of iodide from TH. At first, TH 
deiodinases research focused on their role in maintaining normal serum levels of the 
biologically active molecule T3. Years later it was demonstrated that these enzymes can 
locally modify TH tissular bioactivity independently of the concentrations in serum revealing 
that deiodinases play a much more important role than initially thought (Visser and Peeters, 
2012). Three different types of deiodinases have been identified, with different catalytic 
specificities, tissue distribution, physiological functions, and regulation. 
 
 
Figure 1. Thyroid Hormone structure and metabolism. Iodothyronines are molecules made of two 
phenolic rings bound by an oxygen atom and contain between 2 and 4 iodine (I) atoms. Sequential 
deiodination is the most important metabolic process mediated by deiodinases D1, D2 and D3 that catalyse 
the removal of iodide from TH. 
 
Type I iodothyronine deiodinase (D1, encoded by Dio1) is the only deiodinase with both outer- 
(5’) and inner (5)-ring activities and catalyses the conversion of T4 to the genomically active 
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T3 or to the genomically inactive metabolite reverse T3 (3,3’,5’-triiodothyronine, or rT3). It 
can further catalyse T3 and rT3 to 3,3’-diiodothyronine (T2), also an inactive metabolite at the 
genomic level (Bianco and Kim, 2006) (Figure 1). D1 is expressed predominantly in tissues 
with rapid exchange with blood like liver, kidney and thyroid follicular cells and it is most 
likely localised at the plasma membrane of cells (Baqui et al., 2000). D1 activity is believed to 
be a major source of circulating T3. Nevertheless, the high affinity towards rT3 and other 
inactive metabolites suggests a role in the recovery and recycling of iodine within the organism 
(Schneider et al., 2006). Among the different factors that regulate D1 activity the most 
important one is the regulation by T3. T3 induces Dio1 expression, and this aggravates the T3 
excess commonly found in hyperthyroidism (Koenig, 2005). 
Type II iodothyronine deiodinase (D2, encoded by Dio2) catalyses via outer (5’)-ring 
deiodination the prohormone T4 into the active metabolite T3, and rT3 into T2 (Figure 1) 
(Bianco and Kim, 2006). D2 is localised at the endoplasmic reticulum of cells (Baqui et al., 
2000) in tissues with slow exchange with blood and where local regulation of the intracellular 
concentration of T3 is critical such as the brain, anterior pituitary, brown adipose tissue, 
skeletal muscle, thyroid and  heart (Lavado-Autric et al., 2013). D2 activity is regulated by T4 
at the post-translational level by inducing protein degradation at the proteasome (Steinsapir et 
al., 1998). To a lesser extent, D2 can also be regulated at the transcriptional level with T3 
inhibiting Dio2 expression (Croteau et al., 1996) and with T3 deficit increasing Dio2 
expression (Guadaño-Ferraz et al., 1999). 
Type III iodothyronine deiodinase (D3, encoded by Dio3) catalyses the inner (5)-ring 
deiodination of T4 and T3 into rT3 and T2 respectively, inactivating TH action (Bianco and 
Kim, 2006) (Figure 1). D3 is expressed in brain, skin and foetal tissues such as the uterus and 
the placenta suggesting an important role in protecting the foetus from an excess of T3 (Bates 
et al., 1999, Kester et al., 2004). At the cellular level it is present at the plasma membrane 
(Baqui et al., 2003). D3 is transcriptionally regulated by T3 inducing Dio3 expression (Barca-
Mayo et al., 2011), however, it is also regulated by other factors such as oestrogen and 
progesterone, growth factors, glucocorticoids and growth hormone or even genomic imprinting 
(Reviewed in Hernandez (2005)). 
In the brain deiodinases play an essential role in maintaining appropriate levels of T3. D2 and 
D3 in the brain are developmentally regulated as shown during the rat early postnatal 
development where the maturational patterns of D2 and D3 activities reveal a progressive 
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Figure 2. Deiodinase type 2 (D2) in the brain. (A) Schematic representation of T3 availability to the 
paraventricular nucleus (PVN) of the hypothalamus and to blood vessels in the median eminence. T4 from 
the cerebrospinal fluid (CSF) or the blood vessels enters the tanycytes lining the third ventricle where it gets 
converted into T3 by D2 activity. T3 is released into the CSF for conveyance to the PVN by diffusion or 
directly through the tanycytes processes. (B) Schematic representation of T3 availability to neurons through 
the blood-brain-barrier (BBB). T4 from the BBB enters the astrocytes where it gets converted into T3 by D2 
and transported into the neurons. (C) Dio2 mRNA expression in the postnatal mouse brain, from 
transcriptomic analysis of purified native cell populations using RNA-sequencing (Zhang, 2014). The data 
represent the relative abundance of RNA molecules expressed as RNA fragments per kb of transcript 
sequence per million mapped fragments (FPKM). 
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increase in D2 activity while D3 activity follows the opposite pattern (Kaplan and Yaskoski, 
1981). In adults Dio3 is expressed in neurons throughout the brain (Tu et al., 1999) while Dio2 
is expressed in the glial cells astrocytes  and tanycytes (Guadaño-Ferraz et al., 1997, Tu et al., 
1997). Tanycytes line the lower third of the walls of the third ventricle and send their processes 
to the PVN of the hypothalamus and to the median eminence where they frequently end in 
blood vessels. Therefore D2 in the tanycytes could provide T3 to the cerebrospinal fluid (CSF) 
from where it could diffuse to nearby structures and to the hypothalamic nuclei directly 
through the tanycytes processes and control TRH production (Figure 2 A). On the other hand, 
D2 in the astrocytes is believed to be involved in generating and delivering T3 to nearby 
neurons (Guadaño-Ferraz et al., 1997) (Figure 2 B). Recent transcriptome analysis of mouse 
cerebral cortex has confirmed the expression of Dio2 mRNA in astrocytes; in some neurons 
verifying early indications for expression in some interneurons, especially in hypothyroid 
conditions (Guadaño-Ferraz et al., 1999), and has additionally detected Dio2 at 
oligodendrocyte precursor cells (Zhang et al., 2014) (Figure 2 C). 
 
1.3 Thyroid hormone transporters 
Because of the lipophilic nature of TH, it was believed that they could cross the cell membrane 
through passive diffusion. Then, in 2004 the description of mutations in a gene encoding for a 
cell membrane TH transporter that led to severe neurological alterations, established the 
importance of TH transport (Dumitrescu et al., 2004, Friesema et al., 2004). To date, several 
families of transporters with the capacity to transport TH have been described: 
monocarboxylate transporters (MCTs), sodium/taurocholate co-transporting polypeptide 
(NTCP), L-type amino acid transporters and organic anion-transporting polypeptide (OATPs). 
‐ MCTs 
The MCTs are proteins of 426 to 565 amino acids with 12 transmembrane domains, which 
transport monocarboxylates like pyruvate, lactate, ketone bodies, carnitine and aromatic amino 
acids. Most of the MCTs take up the substrates together with a proton, and they can also 
facilitate efflux of their ligands, however, two members of this family function as proton-
independent TH transporters: MCT8 and MCT10 (Halestrap, 2012).  
MCT8 (encoded by SLC16A2) is highly specific for T3 and T4 transport, but it can also 
transport rT3 and T2 (Friesema et al., 2003). Due to the remarkable pathophysiological 
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manifestations that arise from mutations in MCT8, this transporter will be described in further 
detail below. 
MCT10 (encoded by SLC16A10) transports aromatic amino acids as well as T3 and T4. It is 
slightly more efficient than MCT8 in transporting T3, and less efficient in transporting T4. In 
the mouse brain, Slc16a10 is expressed in neurons and in neural cells in the white matter 
(Müller and Heuer, 2014). 
‐ NTCP 
NTCP (encoded by SLC10A1) or the liver sodium/taurocholate cotransporter, is a seven 
transmembrane domain glycoprotein that belongs to the family of sodium-dependent organic 
anion transporters. It is expressed in hepatocytes and its main function is the transport of 
conjugated bile acids in liver, but it can also transport unconjugated bile acids and other 
amphipathic compounds. Furthermore, transport of the iodothyronines T4, T3, rT3, and T2, as 
well as their sulphated forms T4S and T3S, has been described for this transporter (Friesema et 
al., 1999). 
‐ L-type amino acid transporters 
The L-type amino acid transporters are heterodimeric proteins that consist of a heavy and a 
light chain linked through a disulfide bond. The light chain possesses 12-transmembrane 
domains while the heavy chain presents a single transmembrane domain. These proteins 
mediate the transport of neutral amino acids like leucine, phenylalanine and tyrosine. The 
sodium-independent transporters LAT1 (large neutral amino acids transporter small subunit 1, 
encoded by SLC7A5) and LAT2 (large neutral amino acids transporter small subunit 2, 
encoded by SLC7A8) can transport as well T4 and T3 (Friesema et al., 2005). In the developing 
mouse brain Lat1 and Lat2 mRNA are largely expressed in neurons, oligodendrocyte precursor 
cells, microglia, and are very abundant in endothelial cells of the blood-brain-barrier (BBB). 
Lat1 mRNA is also present in the astrocytes (Bernal et al., 2015). 
‐  OATPs 
The OATP transporter family comprises proteins with 12 transmembrane domains responsible 
for the sodium-independent transport of amphipathic organic compounds, such as steroids, bile 
salts, drugs and anionic oligopeptides. Studies in vitro have revealed that at least 7 human 
OATPs and 14 mouse OATPs can mediate TH transport. The mouse postnatal brain expresses 
the transporters Oatp1c1 (encoded by Slco1c1), Oatp1a4 (encoded by Slco1a4) in endothelial 
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cells, Oatp3a1 (encoded by Slco3a1) in oligodendrocytes and Oatp2b1 (encoded by Slco2b1) 
in endothelial cells and microglia. Of especial relevance is the Oatp1c1 transporter that 
transports T4, rT3 and T4S with high specificity, and in the developing mouse brain, is present 
in astrocytes and endothelial cells of the BBB and the choroid plexus (Bernal et al., 2015, 
Roberts et al., 2008, Sugiyama et al., 2003). 
 
1.4 Mechanism of thyroid hormone action 
The main pathway of TH action is at the genomic level regulating gene expression through the 
binding of T3 to its nuclear TH receptors (TRs) which function as ligand-activated 
transcription factors.  TRs belong to the nuclear receptor superfamily and are encoded by two 
different genes, THRA and THRB in humans (Thra and Thrb in rodents). THRA encodes the 
isoforms TRα1, TRα2, ΔTRα1 and ΔTRα2 and THRB encodes TRβ1 and TRβ2. Only three 
TRs display full receptor function at the genomic level: TRα1, TRβ1 and TRβ2. They present 
three distinct domains: an amino-terminal domain that is involved in the regulation of 
transcription, a DNA binding domain that is a highly conserved domain that recognises the TH 
response elements (TRE) in the DNA and a carboxyl-terminal ligand-binding domain that 
binds TH as well as coregulators that can be either corepressors or coactivators (Cheng et al., 
2010). The receptor can bind the DNA as a monomer, as homodimer or most frequently as 
heterodimer with the 9-cis retinoic acid receptor (RXR) (Force et al., 1994). 
Genes that are induced by T3 and repressed in hypothyroidism are identified as “positively 
regulated genes” while genes repressed by T3 and induced in hypothyroidism are defined as 
“negatively regulated genes”. All of them will be referred as T3-dependent or T3-responsive 
genes. 
When TRs are bound to the DNA in absence of T3 (unliganded TR or apoTR), T3-dependent 
genes display basal levels of transcription. For positive target genes, in the absence of T3, the 
heterodimer RXR-apoTR is bound to the TRE where it interacts with different corepressor 
proteins with histone deacetylase activity that compact the chromatin repressing transcription 
(Grunstein, 1997). Upon the binding of T3 to the TR, there is a conformational change in the 
receptor that leads to the release of corepressor proteins and the recruitment of coactivator 
proteins with acetylase activity that in turn activate the transcription of the target gene (Li et 
al., 1999).  In the case of negative regulated genes, the basal levels of transcription are 
inhibited upon the binding of T3 (Wang et al., 2009). 
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Because the ultimate effect of TH action is the regulation of gene expression, analysis of the 
expression of T3-dependent genes offers an additional tool to monitor the thyroidal status of 
different tissues. This approach has been widely used in the present work. 
In addition to genomic actions, both T3 and T4 can exert non-genomic actions through 
receptors in the plasma membrane, cytoplasm or mitochondria. These receptors can have 
similar structures to those that mediate transcriptional actions of T3, like truncated TRα 
isoforms, or they can share no homologies with TRs such as the plasma membrane receptor 
integrin αvβ3. They can mediate processes such as angiogenesis, cell proliferation, intracellular 
microfilament organization or cellular respiration in the mitochondria expanding the amount of 
cellular events controlled by TH (Davis et al., 2016).  
 
2. Thyroid hormone action in brain 
 
2.1 Brain barriers 
The passage of substances from the blood to the brain is regulated by the BBB and the blood-
cerebrospinal fluid barrier (BCSFB). These barriers tightly control the influx and efflux of 
molecules and ions at the blood-brain interface to meet neuronal needs and to protect the brain 
from toxins and pathogens. The endothelial cells that compose the brain capillaries of the BBB 
have continuous intercellular tight junctions and contain few transcytotic vesicles which limit 
the passage of molecules through the endothelial cells. Thus, substances must leave the 
circulation and enter the brain parenchyma through transcellular transport (Obermeier et al., 
2013). The astrocytes end-feet englobe the outer surface of the endothelium and regulate some 
features of the BBB (Abbott et al., 2006). 
The BCSFB is formed by the epithelial cells lining the ventricular side of the choroid plexus. 
Studies in the rat revealed that the contribution of the choroid plexus to the total brain TH 
content is around 20% (Chanoine et al., 1992) and, since the BBB surface area is much greater 
than that of the choroid plexus, the BBB has been considered the major pathway for TH entry 
into the brain. However, the BCSFB could have a more important role during early 
development as it has been shown that the choroid plexus may have a greater transport 
capacity during early stages of brain growth and development (Keep and Jones, 1990). 
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2.2 Sources of thyroid hormones in the foetal and adult brain 
In the brain several regulatory mechanisms control the concentrations of T4 and T3 in a very 
efficient fashion. These include secretion by the thyroid gland, TH transport to the brain, 
expression of deiodinases and, in the foetus, transplacental passage of maternal TH. 
Studies in adult hypothyroid rats revealed that constant infusion of T3 at relatively low doses 
was enough to normalise T3 levels in peripheral tissues such as liver, kidney, heart or lung 
while much higher doses were necessary for the cerebral cortex to reach normal values. On the 
other hand, when T4 was administered, T3 values were normalised in the cerebral cortex at 
lower doses than those necessary to restore T3 levels in other peripheral tissues. Furthermore, 
T3 content in the cerebral cortex remained within the physiological range regardless of the 
increase in the dose of the T4 administered (Escobar-Morreale et al., 1999). This indicates that 
T4 is the primary source of T3 in the brain and that local conversion of T4 into T3 is tightly 
regulated avoiding excess of T3.  
A model of T3 availability to neural cells has been proposed (Guadaño-Ferraz et al., 1997) and 
validated (Galton et al., 2007, Trajkovic et al., 2007, Dumitrescu et al., 2006). The model 
states that brain T3 has a double origin: a fraction is available directly from the circulation, and 
another is produced locally from T4 in the astrocytes by D2. In order to enter the brain, 
circulating T4 and T3 need to cross the brain barriers through specific TH transporters. Based 
on the location of these transporters the current model supports that (i) T3 and T4 cross the 
BBB through Mct8 into the extracellular fluid where they can directly reach the neural cells in 
the proximity of the blood vessels and that (ii) T4, but not T3, crosses the BBB through 
Oatp1c1 directly into the astrocytes through their end-feet in contact with the blood vessels, 
and produce additional T3 by D2 activity that can be then transported to the neuron (Morte and 
Bernal, 2014) (Figure 3 A). In primates, as OATP1C1 expression at the BBB is very low 
(Roberts et al., 2008), T4 transport through the BBB is believed to be mostly dependent on 
MCT8. 
Studies in rodents suggest that each of these two routes contributes at least 50% to the total 
pool of brain T3 in the adult brain. D2 deficient mice at postnatal day 15 (P15) present around 
a 50% decrease in the content of T3 in the cerebral cortex (Galton et al., 2007) and 40% 
decrease at 3 months of age (Bárez-López et al., 2014).  Furthermore, Mct8 deficient mice also 
present a 50% reduction in the content of T3 in the cerebral cortex (Trajkovic et al., 2007, 
Dumitrescu et al., 2006). Together these data suggest that in the postnatal brain of mice around  
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Figure 3. Sources of T3 in the postnatal and foetal brain. (A) In the adult brain, T3 from the circulation 
crosses the BBB through Mct8 transporter and directly access the neurons in the brain where it binds to the 
TR– RXR heterodimer and regulate gene expression. Also, T4 from the circulation can cross the BBB 
through Oatp1c1 transporter and reach the astrocytes where is converted into T3 by D2 activity. Passage of 
T3 from astrocytes to neurons is then facilitated by Mct8 and also other transporters. (B) In the foetal brain 
the main source of T3 is through deiodination of T4. The contribution of TH transporters to T3 brain 
availability during the foetal period is still not well understood. Modified from Morte and Bernal, (2014). 
 
 
50% of the total brain T3 derives directly from T3 uptake from the circulation and another 
50% is locally generated in the astrocytes. 
On the contrary, during foetal development the brain depends almost entirely on the T3 locally 
generated by D2 in the astrocytes as has been demonstrated in studies in rats (Figure 3 B). 
Administration of high doses of T3 to hypothyroid pregnant rats were able to cross the placenta 
but failed to normalise T3 content in the foetal brain and to induce the expression of T3-
dependent genes. In contrast, physiological doses of T4 could cross both the placenta and the 
foetal brain barriers normalising foetal brain T3 concentrations by T4 deiodination and 
increasing neuronal gene expression (Calvo et al., 1990, Grijota-Martínez et al., 2011). The 
role of D2 activity in this process is further supported by D2 activity ontogeny studies that 
revealed a significant D2 activity in rat foetal brain that highly increased prior to birth and that 
was inversely regulated by increasing doses of T4 (Ruiz de Oña et al., 1988). The reason why 
the foetal brain is not permeable to T3 is not known and cannot be explained by lack of the 
Mct8 transporter as it is present at the BBB during foetal development (Grijota-Martínez et al., 
2011). 
   
13 
 
Introduction 
2.3 Ontogeny of thyroid hormone action in rat brain 
The rat as an animal model has provided most of the current knowledge about thyroid 
physiology and TH action in brain. In the rat, embryonic tissues are provided with T4 and T3 
from at least embryonic day 11 (E11) (Obregon et al., 1984) which is well before the onset of 
foetal thyroid gland function, that in the rat starts after E17. As the foetal thyroid gland starts 
functioning, the proportion of foetal TH increases while the maternal decreases and at term 
about 17.5% of the foetal extra thyroidal T4 pool is of maternal origin (Morreale de Escobar et 
al., 1990).  
The few studies reporting T3 and T4 content in the developing rat brain have been restricted to 
periods coinciding or following the onset of foetal thyroid function at E17 - E21 (Morreale de 
Escobar et al., 1985), however, there is evidence that maternal TH is necessary before the onset 
of the foetal thyroid function as maternal hypothyroidism leads to defects in the proliferation 
of some neuronal precursors that is usually completed by E12 (Narayanan and Narayanan, 
1985) or to defects in the migration of some proliferating cells that normally finishes at E16-
E17 (Lucio et al., 1997). mRNA for TRs has been detected from E11.5 at the neural tube and 
from E12.5 in certain areas of the prosencephalon, mesencephalon and the rhombencephalon 
(Bradley et al., 1992). In addition, T3 binding assays in brain have revealed the presence of 
TRs bound to T3 from E14 with the concentration of binding sites increasing progressively 
until E17 and remaining until birth (Perez-Castillo et al., 1985). In the rat, deiodinase activity 
assays have detected increasing D2 activity in the brain during development from as early as 
E17 until the day prior to birth (Ruiz de Oña et al., 1991) (Figure 4). Therefore, TH could 
exert an action in restricted brain regions or groups of cells during early stages of development 
and have a clear role during late gestation. 
Furthermore, the contribution of maternal TH to foetal development under euthyroid 
conditions still remains unclear. One study revealed that foetuses coming from 
thyroidectomised pregnant rats presented only a small decrease in the brain content of T4, with 
no changes in T3 content at E21 so the gene expression of T3-dependent genes was 
accordingly unaffected in comparison to foetuses coming from control pregnant dams (Grijota-
Martínez et al., 2011). Likewise, in another study, brain D2 activity of foetuses coming from 
thyroidectomised pregnant rats was not different from those coming from control dams (Ruiz 
de Oña et al., 1988). These findings can be attributed to the progressive activity of the foetal 
thyroid gland. 
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Figure 4. Ontogenesis of thyroid hormone action during foetal development in the rat. In the rat, before 
the onset of foetal thyroid function at E17, embryonic tissues are already provided with T4 and T3 from E11. 
The proportion of foetal T4 gradually increases after the foetal thyroid gland starts functioning. In the brain, 
TRs mRNA expression from E11.5 and T3-bound TRs from E14 suggest an early role for thyroid hormone 
action. D2 activity as well as T4 and T3 content are present in the foetal brain from at least E17. Dimensions 
of the figures do not represent relative abundance. 
 
 
Nevertheless, it seems clear that deiodination of T4 (whether maternal or foetal) is the major 
source of T3 to the foetal brain (Escobar-Morreale et al., 1999), at least during late gestation, 
and also that in foetal hypothyroid conditions, maternal T4 can protect the foetal brain 
(Grijota-Martínez et al., 2011, Calvo et al., 1990). 
Due to the advantages of using genetic engineering approaches to generate genetically 
modified animals in mice over rat, the mouse has lately become the most widely used model to 
study thyroid physiology and TH action in brain. The use of genetically modified mice is 
providing new insights about thyroid physiological and pathological events. Considering the 
essential role that TH play during brain development it is crucial to explore TH brain 
availability during mouse brain development in order to understand both developmental and 
latter events. To date this has not been extensively studied probably due to technical 
difficulties in the manipulation of mouse perinatal brain such as small amounts of tissue, 
difficulties to process the delicate tissues from these stages without damage or distortion or the 
very specific spatiotemporal working frames. There is also the mistaken tendency to assume 
that mouse embryonic development follows the same pattern as rat. It is therefore essential to 
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clarify some key aspects regarding TH availability and economy in the brain during mouse 
foetal development. 
 
2.4 Thyroid hormone and brain development 
TH are essential for the correct development of the CNS by regulating processes such us 
neurogenesis and glial cell differentiation including neuronal migration, myelination, and 
synaptogenesis in a very specific time window (Bernal, 2015). Much of the current knowledge 
about the actions of TH in brain development arises from indirect evidence obtained by 
studying the consequences of TH deficiency during critical stages of development. Recent 
transcriptomic analysis from our group has revealed a broad role for TH, suggesting that T3 
promotes the transition of gene expression from foetal to adult patterns. T3 induces the 
expression of genes related to processes such as synaptic transmission and neurotransmission, 
chemical homeostasis or ion transport and inhibits expression of genes involved in cell 
division, chromosome segregation and organization during the M phase of cell cycle (Gil-
Ibañez et al., 2015). 
Lack of sufficient TH results in abnormal development and has different functional 
consequences depending on the timing and the cause for TH deficiency. Due to the importance 
of maternal TH contribution to foetal development it is important to define maternal 
hypothyroidism and maternal hypothyroxinemia. The American Thyroid Association defines 
primary maternal hypothyroidism as the presence of elevated TSH concentrations with 
decreased FT4 concentrations for overt hypothyroidism or with normal FT4 concentration for 
subclinical hypothyroidism. Isolated hypothyroxinemia is defined as normal maternal TSH 
concentration in conjunction with FT4 concentrations in the lower 5th or 10th percentile of the 
reference range (Stagnaro-Green et al., 2011). 
- Iodine Deficiency Disorders. Endemic Cretinism 
Iodine deficiency during embryonic development leads to a syndrome known as cretinism that 
manifests as two main forms, which today are considered the extremes of the same condition. 
Historically these two forms were known as neurological or myxedematous. In neurological 
cretinism the thyroid gland appears to be normal and patients are euthyroid, however, they 
present severe mental retardation, bilateral hearing loss, spasticity affecting specially the lower 
limbs, rigidity and bradykinesia (DeLong et al., 1985). In myxedematous cretinism patients 
suffer from hypothyroidsm and thyroid atrophy and as a result they present immature sexual 
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development, short stature, craniofacial abnormalities and in some cases mental retardation, 
although not as severe as in neurological cretinism (Boyages et al., 1988). The reason for these 
different phenotypes is a differential timing in the action (or lack of action) of TH. The clinical 
features characteristic of neurological cretinism suggests lack of TH action during the second 
trimester of pregnancy due to iodine deficiency that causes iodine deprivation to the foetus and 
severe maternal hypothyroxinemia during the first half of pregnancy. However, myxedematous 
cretinism is due to a non-functional foetal and infant thyroid gland during the last trimester of 
pregnancy and the postnatal period. Very often the destruction of the foetal gland is as 
consequence of iodine deficiency and goitrogens in the diet or lack of selenium (Bernal, 2015). 
Both forms of cretinism often coexist in the same population. 
- Congenital Hypothyroidism 
Congenital hypothyroidism results from developmental defects in the thyroid gland itself or 
from impaired synthesis of TH. If not treated shortly after birth, patients present severe mental 
retardation, short stature, constipation, and other hypothyroid symptoms and signs. As the 
success of treatment with TH depends on the severity, onset, and duration of hypothyroidism, 
systematic screening for congenital hypothyroidism in the newborn is essential to prevent 
mental retardation (Krude et al., 2015).  
- Maternal Hypothyroidism and Hypothyroxinemia 
Maternal TH cross the placental barrier and may play a role during embryonic development 
before and after the onset of the foetal thyroid function (Morreale de Escobar et al., 1987). 
There is a considerable transfer of maternal T4 to the foetus near term which can be crucial to 
protect the foetal brain in cases of congenital hypothyroidism (Vulsma et al., 1989). Both, 
maternal hypothyroidism and maternal hypothyroxinemia are associated with reduced 
intelligence quotient (IQ) in children, and increased incidence of Attention Deficit 
Hyperactivity Disorder (Bernal, 2015). To avoid maternal hypothyroxinemia, and to provide 
enough iodine to the foetus, iodine supplementation for women considering conception and 
during pregnancy and lactation is recommended (Morreale de Escobar et al., 2004, Berbel et 
al., 2007). 
- Resistance to thyroid hormone syndromes  
Resistance to thyroid hormone (RTH) syndromes are a group of genetic conditions that lead to 
decreased tissue sensitivity to TH. These include mutations in TH receptors, TH transporters, 
and impaired deiodinase activities (Dumitrescu and Refetoff, 2015). 
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T3 receptor mutations include mutations in the THRB and THRA gene. Patients with mutations 
in TRβ1 and TRβ2 commonly present reduced IQ, learning disabilities, hyperactive behaviour, 
goitre, tachycardia and bone mineralization disorders. Elevated serum TH levels with non-
suppressed TSH usually leads to the diagnosis, which is confirmed by THRB sequencing 
(Takeda et al., 1992). Patients with mutations in the THRA gene were not described until 2012 
and they present growth and developmental delays, skeletal dysplasia, and severe constipation. 
In the serum, they present relatively low T4 and slightly elevated T3 levels, so in this case, 
there is an elevated T3/T4 ratio (Bochukova et al., 2012). Diagnosis is confirmed by THRA 
sequencing. 
Mutations in the TH transporter MCT8 lead to the Allan-Herndon-Dudley Syndrome (AHDS) 
and will be described in detail below. 
Up to now no inactivating mutations in the DIO2 gene in humans have been reported. The only 
inherited defect of intracellular TH metabolism described so far is caused by mutations in the 
selenocysteine insertion sequence binding protein 2 (SBP2) which is a transacting factor 
involved in the co-translational insertion of selenocysteine into selenoproteins (Driscoll and 
Copeland, 2003). The clinical phenotype consists on short stature, delayed bone age and 
unusual thyroid function test abnormalities with high T4, low T3, and normal or slightly 
elevated TSH serum levels (Dumitrescu and Refetoff, 2011).  
 
3. Mutations in the MCT8 transporter 
MCT8 is the only TH transporter with known pathogenic mutations in humans that lead to the 
AHDS. 
3.1 MCT8 
Monocarboxylate transporter 8 (MCT8) is the protein product of the solute carrier family 16 
member 2 gene (SLC16A2 or MCT8) and it is localised in the q13.2 region of the X 
chromosome (Lafrenière et al., 1994). The gene consists of 6 exons and, in humans, there are 
two translation start sites generating two isoforms with different amino acid lengths of 613 or 
539. Mouse Mct8 only generates a 545 amino acid isoform, which is shorter at the N- terminus. 
In both species, the gene codes for a protein of between 58 and 66 kDa with 12 transmembrane 
domains, characteristic of transporter proteins, with the N- and C-terminus located 
intracellularly. At the N-terminal end there is a PEST domain that serves as proteolytic signal, 
 18 
 
Introduction
targeting the protein for rapid degradation (Lafrenière et al., 1994). It has recently been 
demonstrated that the long human MCT8 isoform contains a longer N-terminus which 
enhances ubiquitin-dependent proteasomal degradation affecting the amount of MCT8 protein 
(Zwanziger et al., 2016). MCT8 exists as monomer and homodimer and in humans, MCT8 
dimers are more stable as this complex is more resistant to denaturing conditions (Visser et al., 
2009). 
Mct8 is present in the brain, heart, placenta, lung, kidney, skeletal muscle, and, most strongly, 
in the liver (Friesema et al., 2005). In the brain Mct8 is expressed in astrocytes, neurons, 
oligodendrocyte precursor cells and at the BBB (Bernal et al., 2015) and the choroid plexus 
(Roberts et al., 2008).  
 
3.2 Etiology and clinical manifestations 
In 1944 Allan and colleagues described a sex-linked form of mental retardation with motor 
abnormalities and named it the AHDS (Allan et al., 1944). The syndrome was mapped to a 
locus on chromosome X in 1990 (Schwartz et al., 1990) but it was not until 2004 that 
mutations in the gene encoding for the TH-specific cell membrane transporter MCT8, were 
identified to result in the AHDS in males (Dumitrescu et al., 2004, Friesema et al., 2004). 
MCT8 deficient patients appear normal at birth and the syndrome starts to become evident in 
the first few months showing global developmental delay, severe intellectual disability, lack of 
speech, profound neuromotor impairment with central hypotonia that progresses to spastic 
quadriplegia, dystonic movements, and muscle wasting. As well as the neurological 
component, the syndrome also consists of an endocrine component as patients present altered 
serum concentration of TH with elevated T3, low T4 and rT3, and normal or slightly elevated 
TSH, indicating a defect in TH metabolism (Dumitrescu et al., 2004, Friesema et al., 2004). 
Evaluation of thyroid status, including both T3 and T4, as TSH levels might not be affected, 
can guide the diagnosis until genetic confirmation. Since the first descriptions of mutations in 
MCT8 in 2004 more than 100 families in the world have been diagnosed with the syndrome. In 
Spain, the generation of a MCT8 deficiency clinical guide by Dr Juan Bernal and Dr Beatriz 
Morte allowed for the identification and description of the first patient in 2013 (Lopez-Marin 
et al., 2013) and since then, 4 other cases have been reported. This highlights the importance of 
both being aware of and suspecting this syndrome in order to obtain an early diagnosis.  
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3.3 Treatment 
The therapeutic options for these patients are rather limited. In an initial attempt, since patients 
present low serum T4 levels, treatment with levothyroxine (LT4) was tested with no 
improvement in the neurological function and even further increasing the serum T3 levels that 
worsened the peripheral hyperthyroidism (Biebermann et al., 2005, Zung et al., 2011). To 
avoid the latter, propylthiouracil (PTU) has been administered together with LT4. This 
treatment allows T3 levels to be normalised in peripheral tissues, improving the thyrotoxic 
state, but it does not improve the neurological condition (Visser et al., 2013, Wemeau et al., 
2008). 
In another approach, four young MCT8-deficient patients were treated with the TH analogue 
3,5-diiodothyropropionic acid (DITPA) which is an agonist of the T3 nuclear receptor. This 
treatment normalised the serum TH levels, ameliorating the thyrotoxicosis of peripheral tissues 
but unfortunately no improvements in psychomotor development were observed (Verge et al., 
2012). 
Recently and during the course of this thesis, another TH analogue, 3,3’,5-triiodothyroacetic 
acid (TRIAC), is being considered as an alternative treatment and a clinical trial is being 
developed exploring as a first goal its action at the peripheral level. The outcome of this 
clinical trial so far will be discussed along with some of the results obtained in this thesis in the 
discussion section. 
In summary, the therapeutic strategies currently available are successful in alleviating the 
thyrotoxicosis of peripheral tissues by normalising the circulating levels of T3, but are not able 
to improve the neurological impairments of MCT8 deficient patients. 
 
3.4 Mct8 deficient mice 
Mct8 knockout (Mct8KO) mice were generated as a model for the AHDS. These mice 
faithfully replicate the alterations in the TH concentrations in serum of the patients with high 
T3 and low T4 (Dumitrescu et al., 2006, Trajkovic et al., 2007). Unfortunately, they do not 
present gross neurological abnormalities (Wirth et al., 2009), hence they are only a partial 
model of the disease. Despite of this, they have been a useful tool to understand some aspects 
of the syndrome and to explore the differences between mice and humans. Studies using these 
mice have demonstrated that despite having high serum T3 concentrations, Mct8KO mice have 
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reduced T3 content in the brain (Dumitrescu et al., 2006, Trajkovic et al., 2007) and alterations 
in the expression of some T3-dependent genes (Morte et al., 2010).  
Studies with Mct8KO mice have also suggested that the pathogenesis associated with MCT8 
deficiency arises from an impaired T3 transport across the BBB. In these studies, when 
hypothyroid Mct8KO animals were treated with T4 or T3, T4 was considerably more 
successful in normalising the expression of T3-dependent genes indicating a restricted access 
of T3, but not T4, to neurons. However, T3 action in neurons in vitro was similar in Wild type 
(Wt) and Mct8KO cells suggesting that the main restriction for T3 entry into the neural target 
cells of Mct8KO mice is at the BBB (Ceballos et al., 2009) and not at the neuronal membrane 
as previously believed. Therefore, in the absence of Mct8, T3 cannot enter in sufficient 
amounts to the brain. This has been supported by recent studies of human brain sections that 
have provided evidence for cerebral hypothyroidism in MCT8 deficient patients, already 
present from prenatal stages (López-Espíndola et al., 2014).  
The current hypothesis that explains why Mct8KO mice do not present gross neurological 
abnormalities in contrast to the severe neurological impairments of MCT8 deficient subjects 
supports that the elevated D2 activity, characteristic of Mct8KO mice in the brain (Dumitrescu 
et al., 2006, Trajkovic et al., 2007), enhances local T4 to T3 conversion as a compensatory 
mechanism (Figure 5). It has been proposed that T4 crosses the BBB and/or the BCSFB in the 
absence of Mct8 through an additional transporter. The Oatp1c1 transporter was proposed as a 
candidate to mediate T4 transfer into the brain as it is predominantly localised in capillary 
endothelial cells as well as in choroid plexus structures (Pizzagalli et al., 2002, Sugiyama et al., 
2003) and most importantly, OATP1C1 expression has not been detected in BBB endothelial 
cells of primate brain (Ito et al., 2011). This hypothesis was supported by the generation of 
double knockout (KO) animals lacking both Mct8 and D2 proteins or Mct8 and Oatp1c1 
transporters as both animal models present similar characteristics to hypothyroidism (Morte et 
al., 2010, Mayerl et al., 2014). In addition, the phenotypic outcome of these double knockouts 
further validated the model for TH brain availability described above.   
In summary, Mct8 deficiency in adult mice leads to peripheral hyperthyroidism with T3 excess 
(in the plasma, liver, kidney and muscle) due to complex mechanisms that are not fully 
understood and are summarised in figure 5, and brain hypothyroidism due to T3 deprivation 
(Figure 5). 
Surprisingly, at perinatal stages of development Mct8KO mice exhibit a transient state of brain 
hyperthyroidism with increased brain T4 and T3 content and increased expression of T3-
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dependent genes (Ferrara et al., 2013). The mechanisms underlying this brain hyperthyroidism 
are not well understood but it has been suggested that could be either a result of increased local 
production of T3 from T4, or to retention of T3 in the cortex. This last one could indicate that 
Mct8 mediates T3 efflux and/or degradation of T3 by D3 in neurons (Nuñez et al., 2014). 
 
Figure 5. Changes in TH concentration in Mct8 deficient (Mct8KO) mice. In the plasma, they present 
high T3 and low T4 and rT3. In the absence of Mct8, there is an impaired regulation of the hypothalamic–
pituitary axis as T3 cannot reach the paraventricular nucleus (PVN) of the hypothalamus and the pituitary, 
leading to resistance of the TRH–TSH axis to TH. In the brain, deficient T3 entry reduces deiodination by D3 
contributing to the increased levels of T3 in serum. Although T4 entrance is reduced in the brain, transport 
through the Oatp1c1 transporter allows the conversion of T4 to T3 by increased D2 activity. In the liver, 
increased supply of T3 from the plasma produces liver hyperthyroidism which increases D1 activity 
producing even more T3 from T4. In the kidney, Mct8 deficiency decreases efflux with retention of T4 and 
T3 producing kidney hyperthyroidism that increases D1 activity as in liver. In bone, an alternative transporter 
(Mct10) might mediate T3 transport and action. In brown adipose tissue (BAT), reduced T4 levels increase 
D2 activity, which results in normal T3 concentrations and BAT function. In skeletal muscle, the increased 
T3 content leads to an increase in the energy expenditure. From Bernal et al., (2015). 
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Objectives 
The broad aim of the present study is to explore TH availability and action in mouse brain 
during foetal development in health and disease. Understanding how TH accesses and 
functions in the developing brain, among other things, might allow the design of therapeutics 
and timing of treatments for pathological conditions related to TH, such as for the AHDS. 
Moreover, in the absence of an effective therapy for MCT8 deficient patients, this study has 
aimed to develop treatments for MCT8 deficiency according to the current knowledge. It has 
therefore been divided into two separate parts. 
1. The first part has aimed to explore the sources of T3 that ensure brain euthyroidsm 
during mice foetal development focusing on: 
- the contribution of maternal TH to foetal development, 
- the contribution of TH transporters and deiodinases activities in the foetal brain 
with special attention to D2 activity due to its relevance in the postnatal and adult 
mouse and 
- unravelling the role of D2 in Mct8 deficiency during early developmental stages. 
 
2. The second part has aimed to test novel therapeutic approaches as possible treatments 
for MCT8 deficiency using Mct8KO mice. Taking into account that the main 
restriction for T3 brain entry in MCT8 deficiency is at the BBB, these strategies have 
been: 
-  the use of the TH analogue TRIAC that is not transported by Mct8 and that has the 
ability to cross the brain barriers, 
-  the replacement of MCT8 by adeno-associated virus to try to correct brain defects 
and  
- the administration of TH replacement treatments by intranasal administration, a 
delivery route that can circumvent the BBB. 
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1. Ethics statement 
All experimental procedures involving animals were performed following the European Union 
Council guidelines (directive 2010/63/UE) and Spanish regulations (R.D. 53/2013), and were 
approved by the ethics committee at Consejo Superior de Investigaciones Científicas (CSIC; 
approval numbers 315/14 and 316/14). All efforts were made to minimise suffering, as 
indicated below. 
 
2. Experimental animals 
Animals were housed in temperature- and light-controlled conditions at 22 ± 2° C on a 12:12 
light-dark cycle (lights on at 8 am), and they had access to food and water ad libitum. 
Mct8 (Slc16a2) KO mice (male genotype, Mct8–/y) were originally produced by Dr. Refetoff 
(Dumitrescu et al., 2006) by homologous recombination. Experiments were carried out in 
Mct8+/y and Mct8-/y mice from the same litters derived by backcrossing heterozygous females 
with Wt males of the C57BL/6J strain at our animal facility. The pups were genotyped to select 
for Mct8+/y and Mct8–/y mice from the same litters. For simplicity, these animals will be 
referred to as Wt and Mct8KO mice, respectively. The Mct8 genotype was confirmed by PCR 
of tail DNA (35 cycles at 61° C annealing temperature) using the following primers: forward 
common, 5′-ACAACAAAAAGCCAAGCATT-3′; reverse Wt specific, 3′-
GAGAGCAGCGTAAGGACAAA-5′; reverse Mct8KO specific, 3′-CTCCCA 
AGCCTGATTTCTAT-5′ which generates a 476-bp product corresponding to the Wt allele and 
a 239-bp PCR product corresponding to the null allele. 
Dio2KO (Dio2-/-) mice and Wt counterparts were initially provided by Dr. Galton (Schneider 
et al., 2001) and a colony was established at Instituto de Investigaciones Biomédicas (Madrid, 
Spain) in the same C57BL/6J genetic background. The Dio2 genotype was confirmed by PCR 
of tail DNA (35 cycles at 62° C annealing temperature) using the following primers: forward 
common, 5′-GTTTAGTCATGGAAGCAGCACTATG-3′; reverse Wt specific, 5′-
CATGGCGTTAGCCAAAACTCATC -3′ and reverse Dio2KO specific, 5′-
CGTGGGATCATTGTTTTTCTCT-3′ which generates a 400-bp product corresponding to the 
Wt allele and a 450-bp PCR product corresponding to the null allele. 
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Double Mct8- and D2-deficient mice (Mct8/Dio2KO; Mct8-/y and Dio2-/-) were generated in 
the same C57BL/6J genetic background by mating Mct8-/y and Dio2-/- mice. The Mct8-/y Dio2-/- 
was confirmed by the PCRs procedures described above.  
 
3. Treatments 
 
3.1 Thyroid hormone treatment 
After crossing with Wt male mice, Wt pregnant dams were given either T3 or T4 in the 
drinking water from E12 until the end of the experiment on E18, the day prior to birth. The TH 
concentration was calculated on the basis of fluid intake to provide 1.5 μg T3/100 g body 
weight (BW) or 8 μg T4/100 g BW in the drinking water containing 0.01% bovine serum 
albumin (BSA) and was not corrected for increasing weight. To analyse the relative effects of 
the maternal and the foetal thyroidal status, the following groups were compared: control 
euthyroid dams receiving no hormonal treatment (n = 7); dams treated with 1.5 μg T3/100 g 
BW from E12 (n = 6) and dams treated with 8 μg T4/100 g BW from E12 (n = 7). On 
gestational day E18 dams were killed in a CO2 euthanasia chamber and were perfused with 
saline to remove blood from tissues before their collection. Prior to perfusion, blood was 
extracted by retroorbital collection and used for the determination of T4 and T3 plasma 
concentrations. Embryos were killed by decapitation at E18 and their brains and livers were 
dissected out, blotted on filter paper, frozen on dry ice, and stored at -80° C. 
 
3.2 TRIAC treatment 
Wt and Mct8KO mice from the same litters were given either drinking water or TRIAC 
(Sigma-Aldrich) in the drinking water at P21, concurring with the weaning, until P30. The 
TRIAC concentration was calculated on the basis of fluid intake to provide 30 ng/g BW/day in 
the drinking water containing 0.01% BSA. Animals were killed at P30 two hours after the end 
of the dark cycle, when most of the water intake takes place. 
In one set of experiments, the following groups were prepared: Wt mice (n = 5), Mct8KO mice 
(n = 7), Wt mice treated with TRIAC (n = 5), and Mct8KO mice treated with TRIAC (n = 7). 
The animals were killed by decapitation. Trunk blood was collected in heparinized tubes after 
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decapitation and was used for T3, T4, and TRIAC determinations in plasma. The cerebral 
cortex, striatum, liver and heart were harvested as explained below. These tissues were used 
for gene expression analysis. 
In another set of experiments, Wt mice (n = 7), Mct8KO mice (n = 10), Wt mice treated with 
TRIAC (n = 8), and Mct8KO mice treated with TRIAC (n = 11) were used to determine the T3 
and TRIAC content in the cerebral cortex and the striatum. 
 
3.3 Intranasal treatment 
Intranasal administration was performed as described in Dhuria (Dhuria et al., 2010). Mice 
where anaesthetised with isoflurane (4% for induction, 2% for maintenance in O2, Abbot 
Laboratories, Madrid, Spain). After induction of anaesthesia, mice were placed lying on their 
backs maintaining their head positioned so drainage of the dose solution into the trachea and 
oesophagus was prevented. Because of the protective barriers in the nasal mucosa, typically 
less than 1% of the administered dose reaches the brain so a highly concentrated drug 
formulation is required for intranasal administration.  
In one set of exploratory experiments a high concentrated solution of T4 was intranasally 
administered to three-month-old mice. Mice were euthalized after a long-term treatment (Wt 
basal n = 2, intranasally treated with saline; Wt + T4 n = 3, intranasally treated with T4; 
Mct8KO basal n = 3, intranasally treated with saline and Mct8KO + T4 n = 5, intranasally 
treated with T4) or after a short-term treatment (Wt basal n = 3; Wt+T4 n = 3; Mct8KO basal n 
= 2 and Mct8KO +T4 n = 5).  
In another set of experiments a high concentrated solution of T3 was intranasally administered 
to Wt mice. T3 was administered alone, bound to 1% BSA or bound to 1% BSA in the 
presence of a vasoconstrictor, phenylephrine hydrochloride (PHE; Sigma, P6126). The 
following groups were prepared: 3-month-old Wt basal n = 11 (Wt treated with saline 
intranasally delivered); Wt + T3 n = 11 (Wt treated with T3 intranasally delivered); Wt + T3-
BSA n = 7 (Wt treated with T3 bound to 1% BSA intranasally delivered) and Wt+T3-BSA-
PHE n = 7 (Wt treated with T3 bound to 1% BSA and 1% PHE intranasally delivered). Mice 
were sacrificed after a short-term treatment and brains and plasma were harvested for posterior 
analysis. 
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4. Tissue extraction and processing 
Tissue employed for TH determinations, D1 and D2 activity assays as well as for RNA 
extraction of juvenile or adult mice was obtained by anesthetising the animals with ketamine 
(75 µg/g BW) and medetomidine hydrochloride (1 µg/g BW), and perfused with saline to 
remove blood from tissues before their collection. Prior to perfusion, blood was extracted by 
retroorbital collection and used for TH determinations. Brains were removed, and the cerebral 
cortex and the striatum were rapidly dissected out from the underlying structures. The liver and 
heart were also harvested.  
Wt (n = 14), Mct8KO (n = 14) littermates; Wt (n = 8), Dio2KO (n = 8) littermates; and 
Dio2KO (n = 8), Mct8/Dio2KO (n = 10) littermates at P3 were euthanized by decapitation and 
the cerebral cortices were dissected at 4° C in PBS (phosphate-buffered saline: phosphate 
buffer 0.05 M and 0.9% NaCl, pH 7.4). All tissue was blotted on filter paper, frozen on dry ice, 
and stored at -80° C. 
Tissue employed for histological procedures of juvenile or adult mice was obtained by 
anesthetising the animals with ketamine (75 µg/g BW) and medetomidine hydrochloride (1 
µg/g BW) and perfusing with saline followed by 4% paraformaldehyde in 0.1 M PB 
(phosphate buffer 0.1M, pH 7.4) via injection into the left heart ventricle. Brains were then 
removed and postfixed for 24 h and afterwards embedded in paraffin. Perinatal animals (E15, 
E18, P1, P3) were euthanized by decapitation; the brains were removed and fixed in 4 % 
paraformaldehyde in 0.1 M PB for 24 h and afterwards embedded in paraffin. A minimum of 
two animals per group was used for histological studies. Paraffin blocks containing cerebral 
cortex were cut coronally while those containing cerebellum were cut sagitally into 8 µm thick 
sections that were transferred onto Superfrost Ultra Plus slides (Thermo Scientific). 
 
5. Radioimmunoassays of T4, T3, and TRIAC in plasma and tissues 
T3, T4 and TRIAC determinations were performed in collaboration with Dr. Maria Jesus 
Obregon of the Instituto de Investigaciones Biomédicas “Alberto Sols” in Madrid. 
T3, T4 and TRIAC were labelled with 125I from T2, T3 and DIAC respectively with a high 
specific activity (3,000-1,500 µCi/µg) according to Weeke and Orskov (1973). Products of the 
synthesis were separated by paper chromatography in butanol-methanol-ammonia-water as 
described (Obregon et al., 1978). 
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For postnatal animals, individual 80 µl aliquots of plasma as well as hemicortices and striatum 
of individual mice were extracted for radioimmunoassay (RIA) determinations. For E18 mice, 
hemicerebrums and livers from individual embryos were extracted for RIA determinations. 
Extraction of T3, T4 and TRIAC from the plasma and tissue as well as T3, T4 and TRIAC 
determinations in plasma and tissues, were determined as previously described (Morreale de 
Escobar et al., 1985, Medina-Gomez et al., 2008). When animals had been treated with 
TRIAC, T3 data were corrected for the crossreactivity of TRIAC on the T3 antiserum (17%).  
 
6. D1 and D2 enzymatic activities 
D1 and D2 enzymatic activities were performed in collaboration with Dr. Maria Jesus Obregon 
of the Instituto de Investigaciones Biomédicas “Alberto Sols” in Madrid. 
D1 activity in liver and D2 activity in the hemicortices and hemicerebrums were measured as 
described (Obregon et al., 1989) with minor modifications. In brief, the release of 125I iodide 
from 125I-labeled substrates was measured in tissue homogenates using 0.32 M sucrose, 10 mM 
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), and 10 mM dithiothreitol 
(DTT). 125I-labelled substrates were purified by removing contaminating iodide by 
electrophoresis.  
For D2 activity in hemicortex and hemibrain: 125I-T4 (100,000 – 50,000 cpm/tube), 2 nM T4 + 
1 μM T3, 20 mM DTT, and 1 mM PTU per 100 μl were incubated for 60 min at 37° C using 
20-50 μg protein/100 μl. 
For D1 activity in liver: 125I- rT3 (60,000 cpm/tube) was used in the presence of 200 nm rT3 
and 2 mm DTT, and were incubated for 10 min at 37° C, using 20–50 μg protein/100 μl.  
The 125I iodide released was directly measured in a gamma counter detector. The protein 
content was determined by the method of Lowry et al. (1951) after precipitation of the 
homogenates with 10% trichloroacetic acid to avoid interference from DTT in the colorimetric 
reaction.  
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7. Gene expression 
RNA was isolated from individual hemicerebrums, striatum, hemicerebral cortices, liver and 
heart. Total RNA was extracted using TRIZOL reagent (Invitrogen, 15596026) following the 
manufacture’s recommendations with an additional chloroform extraction. RNA quality 
control was performed with the Agilent 2100 Bioanalyzer. cDNA was prepared from 250 ng 
RNA using the high capacity cDNA reverse transcription kit (Applied Biosystems). For 
quantitative PCR (qPCR), a cDNA aliquot corresponding to 5 ng of the starting RNA was 
used. The real time PCR was performed with the Taqman universal PCR master mix, No Amp 
Erase UNG (Applied Biosystems), on a 7900HT fast real-time PCR system (Applied 
Biosystems). The PCR program consisted in a hot start of 95° C for 10 min, followed by 40 
cycles of 15 sec at 95° C and 1 min at 60° C. PCRs were performed in triplicates, using the 
18S gene as internal standard and the 2-cycle threshold method for analysis. Data were 
expressed relative to the values obtained on tissues from the Wt mice in basal conditions, 
which were given a mean value of 1.0 after correction for 18S RNA. 
The Taqman probes (Applied Biosystems) used in this thesis are listed below:  
Probe ID Gene symbol Full gene name 
Mm00657317_m1 Aldh1a1 aldehyde dehydrogenase family 1, subfamily A1 
Mm00483074_g1 Cbr2 carbonyl reductase 2 
Mm00839358_m1 Dio1 deiodinase type 1 
Mm00515664_m1 Dio2 deiodinase type 2 
Mm00548953_s1 Dio3 deiodinase type 3 
Mm00513052_m1 Flywch2 flywch family member 2 
Mm00498963_m1 Hr hairless 
Mm00434548_m1 Itih3 inter-alpha trypsin inhibitor, heavy chain 3 
Mm00495172_m1 Klf9 kruppel-like factor 9 
Mm00441516_m1 Lat1,  
Slc7a5 
solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 5 
Mm00444250_m1 Lat2,  
Slc7a8 
solute carrier family 7 (cationic amino acid transporter, 
y+ system), member 8 
Mm00486204_m1 Mct8, 
Slc16a2 
solute carrier family 16 (monocarboxylic acid 
transporters), member 2 
Mm00661045_m1 Mct10, 
Slc16a10 
solute carrier family 16 (monocarboxylic acid 
transporters), member 10 
Mm00453126_m1 Oatp1a4, 
Slco1a4 
solute carrier organic anion transporter family, member 
1a4 
Mm00451845_m1 Oatp1c1, 
Slco1c1 
solute carrier organic anion transporter family, member 
1c1 
Mm01201431_m1 Serca2a, 
Atp2a2 
ATPase, Ca2+ transporting, cardiac muscle, slow twitch 2 
Mm00436528_m1 Shh sonic hedgehog 
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8. BSA-T3 binding assay 
This was performed to evaluate the lowest concentration of BSA necessary to bind the 
appropriate concentration of T3 required for intranasal delivery. 
The ability of BSA to bind a T3 replacement dose (Di Cosmo et al., 2009) was also assessed. 
These solutions were incubated for 20 min at room temperature (RT) with 18,000 cpm of 125I-
T3 and in presence of different concentrations of BSA: 0.25%, 0.5%, 1%, 1.5%, 2% and 5%. 
Prior to incubation 125I-T3 was purified by removing contaminating iodide by electrophoresis. 
After incubation samples were precipitated with 10% trichloroacetic acid by centrifuging 30 
min at 2,800 rpm and the supernatants were removed. The 125I-T3 bound to BSA precipitated 
was assessed by measuring the 125I in a gamma counter detector. Percentage of binding was 
calculated by referring these measurements to standard samples solely containing the 18,000 
cpm of 125I-T3. 
 
9. Immunohistochemical and immunofluorescence procedures 
Tissue sections were deparaffinised by incubating the sections 20 min at 65° C prior to three 
incubations with xylenes at RT and then washed in serial dilutions of ethanol in order to 
rehydrate the tissues. Next, tissue sections were incubated 20 min at 95° C with the EnVision 
FLEX Low pH (Dako, K8005) solution for antigen retrieval.  
For diaminobenzidine labelling, endogenous peroxidase was blocked at RT for 15 min with 
3% hydrogen peroxide in distilled water. Afterwards, nonspecific antibody binding was 
prevented by blocking the tissue in PBS containing 0.1% triton X-100, 4% BSA (Sigma, 
A4503) and 5% normal goat serum (Vector Laboratories, S-1000) at RT for 1.5 h. Tissue 
sections were incubated at 4° C overnight with the primary rabbit anti-hMCT8 1:250 (Sigma, 
HPA029308) in PBS containing 0.1% Triton X-100, 4% BSA and 1% normal goat serum. 
After 6 washes with PBS, sections were incubated for 1 h at RT with biotinylated anti-rabbit 
secondary antibodies (Vector Laboratories, BA-1000) at a 1:200 dilution in PBS containing 
0.1% Triton, 4% BSA and 1% normal goat serum. For signal amplification the sections were 
incubated with Avidin-Biotin Complex (Thermo Scientific; Ultra-Sensitive ABC Peroxidase 
Staining Kits, 32050) at RT for 1 h and revealed with diaminobenzidine (5mg/mL, Sigma, 
D5637). Some preparations were counterstained with Harris hematoxylin (Sigma, HHS32). 
Finally, tissues were dehydrated in ascending alcohols, cleared in xylenes, and covered with 
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hydrophobic mounting medium Depex (Serva, 18243). Moreover, in order to verify the 
specificity of the secondary antibody, negative controls were run in parallel without the 
primary antibody. Histological analyses were made under bright field illumination using a 
Nikon Eclipse 80i microscope and photomicrographs were acquired with a Nikon DS-Fi1 
digital camera. 
For immunofluorescence labelling, antigen retrieval, nonspecific binding prevention and 
incubation with primary rabbit anti-hMCT8 were performed as described above with the 
difference that this time the anti-hMCT8 was used at 1:200. The secondary antibody Goat anti-
rabbit Alexa 546 (Molecular Probes, A-11035) was used at a 1:500 dilution in PBS containing 
0.1% Triton, 4% BSA and 1% normal goat serum at RT for 2 h. The sections were posteriorly 
washed 6 times in PBS and incubated with 4’,6-diamidino-2-phenylindole (DAPI, Molecular 
Probes, D1306) 1:500 in PBS. After washing 3 times in PBS, sections were mounted with 
ProLong Gold Antifade Mountant (Molecular Probes, P36930). Omitting the primary 
antibodies in the incubation reaction gave no signal. Confocal images were acquired using an 
inverted Zeiss LSM 710 laser scanning microscope. Images correspond to 4 layers of a z-stack 
and were processed using ImageJ software (1.48v; National Institutes of Health). 
 
10. In situ hybridization 
In situ hybridization was performed in paraffin embedded tissue sections and was executed as 
previously described (Bernal and Guadaño-Ferraz, 2002). Shortly, Dio2 antisense and sense 
riboprobes were synthesized in the presence of 35S-UTP from the D2 cDNA Rattus norvegicus 
template (NM_031720.4; spanning nucleotides 535–901) as described in Guadaño-Ferraz et al. 
(1997) which shares a 95% of similarity with Mus musculus. After deparaffination, hydration 
and permeabilisation, sections were incubated with 9x106 cpm/500µl of the labelled antisense 
riboprobes and sense riboprobes as negative controls overnight at 55° C. Non-specific probe 
binding and the excess probe was washed away in buffers of decreasing salt concentrations at 
increasing temperatures up to 68° C. Sections were then dehydrated in ascending alcohols with 
NH4OAc 0.3M and exposed to photographic film (BioMax, Kodak). After exposure for 60 
days, the films were developed with Kodak D19 and fixed with fixative (Agfa, G354). 
Controls for the specificity of the hybridization included the use of the antisense probe which 
gave no signal. 
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11. Nissl staining 
Sections were deparaffinised and hydrated as explained above and were incubated 15 min with 
0.1% toluidine blue (Merk, 115930). Then they were dehydrated in ascending alcohols, cleared 
in xylenes, and covered with hydrophobic mounting medium Depex (Serva, 18243). 
Histological analyses were made with Nikon Eclipse 80i microscope and photomicrographs 
were acquired with a Nikon DS-Fi1 digital camera as mentioned in the immunohistochemical 
and immunofluorescence procedures section. 
 
12. Statistical Analysis 
Differences between two groups were compared by two-tailed unpaired Student’s t-tests. 
Difference between means of three or more independent samples was done by one-way 
analysis of variance (ANOVA) and the Bonferroni’s posthoc test. To examine the effect of the 
two factors, such as treatment and genotype, data were analysed by two-way ANOVA and the 
Bonferroni’s posthoc test.  
In all of the cases the GraphPad software (www.graphpad.com) was used. Significant 
differences were represented as * p < 0.05; ** p < 0.01 and *** p < 0.001. All other 
comparisons for which the significance is not shown were not significant. 
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PART I: Contribution of maternal hormones and foetal D2 to thyroid 
hormone brain economy during perinatal development in mice 
 
The first goal was to study the relative contribution of maternal T3 and T4 on foetal brain 
development. For this aim, euthyroid pregnant dams were treated with either 1.5 μg of T3/100 
g BW or 8 μg of T4/100 g BW in the drinking water from E12 to the day prior to birth E18. In 
contrast to previous similar studies conducted in rat (Grijota-Martínez et al., 2011, Calvo et al., 
1990), in the present study a state of global hypothyroidism was not induced. Antithyroid 
drugs Methymazole and KClO4, commonly used to induce hypothyroidism, were not used in 
order to avoid the side effects not related to thyroid function and also to avoid blocking the 
foetal thyroid gland. Furthermore, maternal thyroidectomy was not performed as 
thyroidectomy in mice is not as common as in the rat, conceivably because of the difficulty of 
the microsurgical technique. 
At E18 maternal plasma as well as foetal livers and cerebrums were collected to assess the 
effects of the treatments. The following groups were compared: Wt basal dams and foetuses 
(euthyroid dams); Wt + T3 dams and foetuses (euthyroid dams treated with T3) and Wt + T4 
dams and foetuses (euthyroid dams treated with T4).  
 
1.1 Peripheral effect of thyroid hormone treatment in dams and foetuses 
The outcome of the treatment was checked by TH measurements in the dams and foetuses 
(Figure 6). The effects at the periphery were assessed by performing TH measurements in the 
dams’ plasma and, considering the difficulties to obtain plasma samples from E18 foetuses, TH 
determinations were performed in foetal livers assuming that TH content in the liver reflects 
TH levels in plasma. 
T3 treatment caused a 3-fold decrease in the maternal plasma T4 levels probably due to TSH 
suppression and this was reflected on the T4 foetal liver content which also decreased after 
treatment with T3 (Figure 6 A, B). In contrast, while T3 treatment increased T3 maternal 
plasma levels by 4-fold, it did not increase the T3 content in foetal liver (Figure 6 D, E). 
T4 treatment greatly increased T4 levels in maternal plasma and this increase was reflected on 
foetal liver T4 content that also increased (Figure 6 A, B). After T4 treatment, T3 
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concentration increased in maternal plasma to similar levels to that attained by T3 treatment, 
however, T3 content did not increase in foetal liver (Figure 6 D, E).   
The effects of T3 and T4 treatments on the expression of TH transporters on foetal liver were 
studied by gene expression analysis. The selected genes were two TH transporters (Lat1 and 
Lat2) that have been previously described to be up-regulated by T4 (Engels et al., 2015) and 
that are also expressed at E18 (Li et al., 2012). The expression of the TH transporter Mct8 that, 
although it is not upregulated by T4, is expressed in foetal liver (Engels et al., 2015, Li et al., 
2012) was also monitored. The relative expression of these transporters at E18 versus their 
expression on later stages in life was also studied by comparing mRNA expression levels in the 
liver from basal Wt animals at E18 and basal Wt at P30. The results showed that Mct8 
expression in the liver was higher in P30 animals than in E18 embryos and its expression was 
not regulated after treatment at E18 (Figure 7 A, B). In contrast, expression of both Lat1 and 
Lat2 transporters at E18 was diminished after treatment with T3 and T4, although this decrease 
was only statistically significant when treating with T4 (Figure 7 C, E). This differs from what 
has been observed in 4-month-old mice where T4 treatment up-regulated the expression of 
these two transporters (Engels et al., 2015). However, consistent with previous studies (Li et 
al., 2012), the expression of Lat1 and Lat2 was highly enriched in E18 embryos in comparison 
to P30 mice (Figure 7 D, F).  
Why T3 content in the foetal liver did not increase in accordance to the increase in the T4 
content when treating the mothers with T4, might be explained by the lack of D1 activity in the 
foetal liver. In D1 activity assays, D1 activity was not detected in any of the experimental 
conditions (data not shown) showing that D1 is not present in foetal euthyroid liver and that is 
not inducible by hyperthyroid conditions. 
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Figure 6. Thyroid hormones in dams and E18 foetuses. Euthyroid pregnant dams (Wt basal) treated with 
1.5 μg T3/100 g BW/day (Wt + T3) or with 8 μg T4/100 g BW/day (Wt + T4) from E12 to E18. The left 
panels show changes in T4 levels in maternal plasma (A) and T4 content in foetal liver and brain (B, C) 
while right panels show T3 levels in maternal plasma (D) and T3 content in foetal liver and brain (E, F). 
Data are expressed as means ± SE. *p < 0.05, **p < 0.01, and ***p < 0.001 were determined by One-way 
ANOVA and Bonferroni’s post hoc test. + p < 0.05 and +++p < 0.001 were determined by two-tailed unpaired 
Student’s t-test. 
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Figure 7. Gene expression analysis of thyroid hormone transporters in liver. Upper panels show 
comparison of the effect of T3 and T4 treatment on the expression levels of Mct8, Lat1 and Lat2 transporters 
in E18 foetal livers (A, C, E) while lower panels show the relative expression of these transporters at E18 vs 
P30 in liver (B, D, F). Measurements were obtained by qPCR and the data are expressed relative to 18S RNA 
as means ± SE. *p < 0.05, **p < 0.01, and ***p < 0.001 were determined by One-way ANOVA and 
Bonferroni’s post hoc test for the upper panels and by two-tailed unpaired Student’s t-test for the lower 
panels. 
 
 
1.2  Effects of maternal thyroid hormone treatment in foetal brain 
In the foetal brain, T4 content reflected the peripheral T4 status of the foetus: T3 treatment 
decreased the foetal liver T4 content by approximately 3-fold and by 2-fold the brain T4 
content compared to the basal group and, on the other hand, T4 treatment induced a 6-fold 
increase in the foetal liver T4 content and a 1.75-fold increase in the brain T4 content 
compared to the basal group (Figure 6 C). Despite these variations in the T4 brain content, T3 
content remained constant and close to normal control values (Figure 6 F). 
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The expression of the T3-resposive gene Aldh1a1 
(Hernandez et al., 2012) was consistent with the constant 
content of T3 in the brain regardless of the variations in the 
T4 content. Aldh1a1 expression in the foetal brain was not 
affected in any of the experimental conditions (Figure 8 A). 
The comparison of basal Aldh1a1 mRNA expression levels 
in Wt brain between E18 and P30 animals revealed that its 
expression is enriched at P30 (Figure 8 B). 
As brain T3 levels are highly dependent on brain T4 content 
the results suggests the presence of important regulatory 
mechanisms that maintain brain T3 homeostasis. Two of 
these regulatory mechanisms in the brain could be the 
regulation of the TH transport to the brain and the 
regulation of deiodinases activities. 
 
 
 
 
 
1.2.1 Thyroid hormone transporters in foetal brain after maternal treatment 
To evaluate the potential regulation of TH transporters as a compensatory mechanism that 
ensures appropriate delivery of TH to the brain under variations on the concentrations of T4, 
the expression of the main TH transporters in the brain was studied by qPCR. Furthermore, the 
relative expression of these transporters at E18 in contrast to later stages in life was also 
assessed by comparing mRNA expression levels from basal Wt animals at E18 and P30.   
None of the studied transporters (Mct8, Oatp1c1 and Lat2) was differentially regulated after 
T3 or T4 treatment in comparison to the basal Wt (Figure 9 A, C, E), suggesting that 
differential expression of these transporters is not involved in regulating TH delivery to the 
brain at E18 after maternal treatment. 
Figure 8. Gene expression analysis of the T3-dependent gene Aldh1a1 in brain. Comparison of the 
effect of T3 and T4 treatment on the expression levels of Aldh1a1 in E18 brains (A) and the relative 
expression of this gene at E18 vs P30 in brain (B). Measurements were obtained by qPCR, and the data 
are expressed relative to 18S RNA as means ± SE. ***p < 0.001 were determined by One-way ANOVA 
and Bonferroni’s post hoc test for figure A and by two-tailed unpaired Student’s t-test for figure B. 
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Figure 9. Gene expression analysis of thyroid hormone transporters in brain. Upper panels show 
comparison of the effect of T3 and T4 treatment on the expression levels of Mct8, Oatp1c1 and Lat2 
transporters in E18 foetal brains (A, C, E) while lower panels show the relative expression of these 
transporters at E18 vs P30 in brain (B, D, F). (G) Relative mRNA expression of the TH transporters Mct8, 
Oatp1c1 and Lat2 in foetal E18 brain. Measurements were obtained by qPCR, and the data are expressed 
relative to 18S RNA as means ± SE. *p < 0.05 and **p < 0.01 were determined by One-way ANOVA and 
Bonferroni’s post hoc test for comparisons among 3 samples and by two-tailed unpaired Student’s t-test for 
comparisons among 2 samples. 
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While Mct8 mRNA expression was the same at E18 and at P30 (Figure 9 B), the expression of 
both Oatp1c1 and Lat2 was greatly increased in postnatal P30 animals in comparison to E18 
embryos (Figure 9 D, F). Furthermore, the relative expression of these 3 transporters at E18 
was also studied by qPCR. Mct8 appeared to be the most abundant transporter as Mct8 
expression was much higher than Lat2 and Oatp1c1 in foetal E18 brains (Figure 9 G). 
 
1.2.2 Deiodinases in foetal brain 
The possible contribution of deiodinases D3 and D2 activities to the maintenance of T3 brain 
content was also assessed. 
D3 plays an essential role in the control of T3 concentration in developing tissues (Bates, 
1999; Kester, 2004). As there is a good correlation between D3 activity and Dio3 mRNA 
content of tissues (Gereben et al., 2008), Dio3 mRNA quantification by qPCR was used to 
analyse the role of D3. This analysis showed that Dio3 expression in the foetal brain did not 
change after treating the mothers with T3 or T4 (Figure 10 A). This indicates that T3 foetal 
brain homeostasis is not due to variations in the degradation of T3 by D3. Furthermore, the 
relative Wt basal expression of Dio3 at E18 was not different from its expression at further 
stages as P30 (Figure 10 B). 
As D2 activity is highly regulated by T4, activity assays were performed in foetal brain to 
determine D2 activity under the different conditions. T3 treatment to the mothers resulted in a 
reduction of foetal brain T4 content and D2 activity was accordingly increased. On the other 
hand T4 treatment to the mothers led to a pronounced increase in the T4 foetal brain content 
and, under this condition, D2 activity was markedly inhibited (Figure 10 E). This indicates 
that D2 activity is present in mouse foetal brain and is highly responsive to brain T4 
concentrations. 
Because D2 can also be regulated at the genomic level by T3 (Burmeister et al., 1997, Croteau 
et al., 1996, Guadaño-Ferraz et al., 1999), Dio2 expression was studied by qPCR. Dio2 gene 
expression did not change in response to T3 or T4 treatments (Figure 10 C) indicating that, 
under the present conditions, regulation of D2 activity at E18 is not at the transcriptional level. 
Moreover, despite the key role that D2 plays at E18 its expression was much more abundant in 
later stages such as P30 (Figure 10 D). 
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Figure 10. Deiodinases 3 and 2 in brain. Figures A and C compare the effect of T3 and T4 treatment on the 
expression levels of Dio3, and Dio2 in E18 foetal brains. Figures B and D show the relative expression of 
these deiodinases at E18 vs P30 in brain. Measurements were obtained by qPCR, and the data are expressed 
relative to 18S RNA. Figure E shows the effect of T3 and T4 treatment on D2 enzymatic activity in foetal 
E18 brains as means ± SE. **p < 0.01 and ***p < 0.001 were determined by One-way ANOVA and 
Bonferroni’s post hoc test for figures A, C and E and by two-tailed unpaired Student’s t-test for B and D. 
 
Due to the key role of D2 in the regulation of T3 brain levels, it was of great importance to 
analyse its expression at a histological level. Despite the efforts that were put into validating 
anti-D2 antibodies (Santa Cruz, sc-98716 and sc-69559) to study D2 protein expression in 
mouse brain through western blot and immunohistological procedures, the specificity of these 
antibodies for D2 could not be satisfactorily proven. Instead, Dio2 mRNA expression was 
analysed by in situ hybridization both at foetal stages (E15 and E18) and at early postnatal 
stages (P1 and P3) to characterise Dio2 expression pattern throughout development. Film 
autoradiograms from representative coronal sections at different brain levels are shown in 
Figure 11 along with the corresponding histological sections stained with Nissl. 
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Figure 11. In situ hybridization on sections of E15, E18, P1 and P3 perinatal mouse brain showing the 
regional distribution of Dio2 mRNA. Representative coronal sections of anterior brain levels are shown on 
the left and representative coronal sections of posterior brain levels are shown on the right. Film 
autoradiograms along with the corresponding histological sections stained with Nissl are shown in each case. 
I, II, III, superior layers of the cerebral cortex; chp, choroid plexus; CPu, caudate putamen (striatum); DG, 
dentate gyrus; hf, hippocampal fissure; LO, lateral olfactory tract; LV, lateral ventricles; ME, median 
eminence and mng, meninges. Scale bars 500 µm. 
 
 
At E15 Dio2 mRNA expression was visible in the ependymal layer of the lateral ventricles 
(LV) and the choroid plexus (chp). Later on it was also detected in the meninges (mng), the 
striatum (CPu), the lateral olfactory tract (LO) and the upper layers of the cerebral cortex (I, II, 
III). At P1 and P3, Dio2 expression was also detected in the hippocampus, especially the 
dentate gyrus (DG), the hippocampal fissure (hf) and the median eminence (ME) resembling 
the already described Dio2 expression in rat at P15 (Guadaño-Ferraz et al., 1997). Dio2 
expression in the ependymal layer of the lateral ventricles, the choroid plexus and the 
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meninges suggests that D2 might be mediating the conversion of T4 into T3 in the brain 
barriers from as early as E15 providing an essential source of T3 to the brain during mouse 
foetal development. 
 
1.3 Role of D2 in Mct8 deficiency during early brain development 
Given the apparent role of D2 in the local generation of brain T3 during development, we 
analysed its possible contribution to the brain hyperthyroidism that paradoxically present 
Mct8KO mice during the perinatal period. To this aim, the expression of a set of T3-dependent 
genes was compared in the genotypes Wt, Mct8KO, Dio2KO and the double KO 
Mct8/Dio2KO animals. 
Mct8KO mice display a brain hyperthyroid state from at least E18 (Ferrara et al., 2013) that is 
more obvious at early postnatal stages (Nuñez et al., 2014). We compared the expression of the 
T3-responsive genes Hr, Shh and Klf9 in the cerebral cortex of Wt, Mct8KO, Dio2KO and 
Mct8/Dio2KO animals on P3. This was done by comparing animals from the same litter so the 
following groups were prepared: Wt and Mct8KO; Wt and Dio2KO and finally Dio2KO and 
Mct8/Dio2KO. 
On P3, Mct8KO animals displayed a state of brain hyperthyroidism with elevated expression 
levels of Hr and Shh in comparison to Wt animals. Klf9 only showed a modest non statistically 
significant increased expression. On the contrary Dio2KO mice presented a state of brain 
hypothyroidism as the expression levels of Hr and Shh were decreased in comparison to Wt 
animals. In this situation, Klf9 expression was slightly decreased, although this decrease was 
not statistically significant. The expression profiles of these T3-dependent genes in the double 
Mct8/Dio2KO were the same as in the single Dio2KO animals; hence Mct8/Dio2KO presented 
a state of brain hypothyroidism in comparison to Wt animals. Expression of the gene encoding 
for the TH transporter Mct8 did not change in the absence of D2 (Figure 12). 
Juvenile and adult Mct8KO mice have an increased D2 activity in brain as a consequence of 
the decreased T4 supply (Dumitrescu et al., 2006, Trajkovic et al., 2007). Whether an 
increased D2 activity in the P3 Mct8KO mice could be responsible for an increased T3 
formation and local brain hyperthyroidism was assessed. However, D2 enzymatic activity 
assays revealed that D2 activity was not altered in the cerebral cortex of Mct8KO animals at P3 
in comparison to Wt littermates. D2 activity in Mct8KO mice at P30 was remarkably increased 
in comparison to the Wt as already described (Figure 13). 
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Figure 12. Gene expression analysis of T3-dependent genes (Hr, Shh and Klf9) in the cerebral cortex of 
Wt, Mct8KO, D2KO and double Mct8/D2KO mice at P3. Animals from the same litter were compared: 
Wt and Mct8KO; Wt and D2KO; D2KO and Mct8/D2KO. The bottom of the panel shows gene expression 
analysis of TH transporter Mct8 between Wt and D2KO animals in the cerebral cortex at P3. Measurements 
were obtained by qPCR, and the data are expressed relative to 18S RNA as means ± SE. **p < 0.01 and ***p 
< 0.001 were determined by two-tailed unpaired Student’s t-test using the respective controls for each case. 
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Figure 13. Enzymatic D2 activity in cerebral cortices of Wt 
and Mct8KO animals at P3 and at P30. Data are expressed as 
means ± SE. ***p < 0.001 was determined by One-way ANOVA 
and Bonferroni’s post hoc test. 
 
 
 
 
 
 
 
 
PART II: Therapeutic approaches for MCT8 deficiency 
As introduced, the current therapeutic strategies used in MCT8 deficiency have been 
successful in normalising the circulating levels of T3 which alleviates the thyrotoxicosis of 
peripheral tissues; however, none of the treatments has improved the neurological deficits in 
these patients. 
In this part of the thesis we have used Mct8KO mice to perform preclinical studies to test 
different approaches in order to develop therapeutic strategies for MCT8 deficiency. Despite 
the fact that Mct8KO mice do not reproduce the neurological deficits of the patients they 
provide a good model to assess the effects of different therapies. Mct8KO mice replicate the 
patient’s endocrine syndrome, which enables the evaluation of the effects of treatments on 
serum TH levels. Furthermore, even though Mct8KO animals do not faithfully replicate the 
severe neurological impairments of patients, T3 and T4 content in the brain is decreased 
approximately by half. This leads to alterations in the expression of some T3-dependent genes 
(Morte et al., 2010) that can be used as markers to evaluate therapeutic actions in the brain. 
Moreover, Mct8KO mice have already been successfully used to study the effect of TH 
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analogues as possible treatments for MCT8 deficiency (Di Cosmo et al., 2009, Ferrara et al., 
2014, Ferrara et al., 2015). 
Because MCT8 deficient patients present cerebral hypothyroidism in combination with 
peripheral hyperthyroidism the design of an appropriate treatment is rather challenging. 
Therapeutic strategies should improve the neurological defects derived from TH deficiency in 
the brain and improve the peripheral thyrotoxicosis. As the main restriction for T3 entry into 
the target neural cells is at the BBB the approaches used here have focused on overcoming the 
limitation at the BBB by the use of TH analogues, of gene therapy strategies and by using 
novel administration routes for brain TH replacement therapy.  
 
2.1 Thyroid hormone analogues: TRIAC 
 
2.1.1 Background  
TRIAC is a natural TH metabolite that displays properties that make it a good candidate as a 
therapeutic agent in MCT8 deficiency. To start with, TRIAC binds with the same affinity as T3 
to the TRα and with higher affinity to the TRβ (Messier and Langlois, 2000). Furthermore, 
TRIAC is already available for clinical use and there is extensive clinical experience, as it has 
successfully been used in patients with thyroid cancer (Müeller-Gäertner and Schneider, 1988) 
and mutations in THRB (Anzai et al., 2012, Stagi et al., 2014). Moreover, in vitro and in vivo 
studies in mice have demonstrated that (i) TRIAC is generated from TETRAC by D2 activity; 
(ii) that it is metabolized by D3 in the same way as T3; but most importantly that (iii) it is 
transported into brain cells by other transporters than MCT8, (iv) that induces similar neuronal 
gene responses as T3 and (v) that is able to restore neuronal differentiation in the hypothyroid 
brain (Horn et al., 2013, Kersseboom et al., 2015). 
However, the fact that TRIAC produces similar gene responses as T3 was assessed only in 
vitro, and the in vivo studies concluding that TRIAC restores neuronal differentiation in the 
hypothyroid brain of the athyroid Pax8 KO and the double Mct8/Oatp1c1 KO mice were 
obtained using high doses of TRIAC (200 – 400 ng/g BW), while lower doses of 50 ng/g BW 
only had modest effects (Kersseboom et al., 2015). As in human clinical trials TRIAC has been 
used at doses ranging from 5 to 50 µg/kg BW/day (Müeller-Gäertner and Schneider, 1988, 
Anzai et al., 2012, Stagi et al., 2014), here the effect of therapeutic doses of TRIAC (30 ng/g 
BW/day) on Mct8KO mice was evaluated to characterise its effects as a potential therapeutic 
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agent in MCT8 deficient patients. And as most patients are diagnosed after birth, the study was 
performed in juvenile mice in order to have comparable conditions to patients. 
For these reasons the design of the treatment consisted on the administration of therapeutic 
doses of 30 ng of TRIAC/g BW/day in the drinking water from P21 until P30 to Wt and 
Mct8KO mice. At P30 brains and peripheral tissues were harvested after saline perfusion to 
assess TRIAC effect so the following groups were compared: Basal Wt; Wt + TRIAC; Basal 
Mct8KO and Mct8KO + TRIAC. 
 
2.1.2 Effects of TRIAC on plasma thyroid hormone levels 
Because patients suffer from peripheral tissue hyperthyroidism, the initial aim was to assess 
the effects of TRIAC on plasma TH levels. 
TRIAC treatment increased nearly by 3-fold TRIAC plasma levels in comparison to untreated 
control animals, and reached the same concentration in both the Wt- and Mct8KO-treated mice 
(Figure 14 A). Plasma T4 levels in the untreated Mct8KO animals were decreased to nearly 
half the levels of the Wt, as already characterised in Mct8 deficiency (Dumitrescu et al., 2006, 
Trajkovic et al., 2007). TRIAC treatment drastically reduced the plasma T4 levels more than 
70% in the treated animals of both genotypes in comparison to their respective basal controls 
(Figure 14 B), so T4 levels in TRIAC-treated Mct8KO animals were 6 times lower than in 
untreated Wt animals. TRIAC is known to have TSH-inhibitory effects (Beck-Peccoz et al., 
1988, Bracco et al., 1993, Everts et al., 1994) causing a decrease of plasma T4 (Medina-Gomez 
et al., 2008). Although TSH was not measured in this study, the decrease in the T4 plasma 
levels both in the Wt and the Mct8KO animals suggests that Mct8 deficiency does not interfere 
with the feedback regulation of TSH by TRIAC. Basal plasma T3 levels were significantly 
higher in Mct8KO compared with Wt animals as previously described. Remarkably, TRIAC 
treatment decreased T3 in the Mct8KO to normal levels while it did not affect T3 levels in the 
Wt mice (Figure 14 C). 
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Figure 14. Triiodothyroacetic acid (TRIAC, A), T4 (B) and T3 (C) plasma levels in Wt and Mct8KO 
mice in basal conditions and after treatment with 30 ng/g BW/day of TRIAC. Data are expressed as means ± 
SE. **p < 0.01, and ***p < 0.001 were determined by two-way ANOVA and Bonferroni’s post hoc test, the 
two factors being genotype and treatment. 
 
 
2.1.3 Effects of TRIAC on the liver and heart 
To further analyse the effects of TRIAC on peripheral organs we studied D1 activity and Dio1 
mRNA expression in the liver as D1 has been shown to be a sensitive marker of the peripheral 
thyroid status in the mouse (Zavacki et al., 2005). The study of D1 enzymatic activity in the 
liver displayed the well-characterised increase of this enzyme in Mct8KO animals compared 
with the Wt animals (Dumitrescu et al., 2006, Trajkovic et al., 2007). TRIAC treatment 
increased D1 activity both in the Wt and Mct8KO animals (Figure 15 A) despite a decrease in 
the plasma T3 levels, probably due to the effect of TRIAC as a TR agonist. Consistent with the 
D1 activity results, Dio1 mRNA expression levels were increased in the Mct8KO compared 
with the Wt animals. TRIAC treatment increased Dio1 expression 5-fold in the Wt mice and 
1.5-fold in the Mct8KO mice in comparison to their basal levels (Figure 15 B), confirming the 
thyromimetic activity in the liver. Taken together, the findings indicate that TRIAC, similar to 
T3, has a direct effect on the liver regulating Dio1 mRNA expression and D1 activity. 
TRIAC effect in the heart was evaluated by analysing the expression of the T3-responsive gene 
Serca2a. TRIAC treatment did not have an effect on the expression of Serca2a neither in the 
Wt or the Mct8KO animals (Figure 15 C).  
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Figure 15. Liver D1 enzymatic activity (A) and gene expression analysis of Dio1 (B) in the liver and 
Serca2a (C) in the heart in Wt and Mct8KO mice in basal conditions and after TRIAC treatment. Gene 
expression measurements were obtained by qPCR, and the data are expressed relative to 18S RNA as means 
± SE. **p < 0.01, and ***p < 0.001 were determined by two-way ANOVA and Bonferroni’s post hoc test, 
the two factors being genotype and treatment.  
 
 
2.1.4 Effects of TRIAC in the brain 
As all the current available treatments for MCT8 deficiency have failed to improve the 
neurological condition, the ultimate goal was to analyse the effect of therapeutic doses of 
TRIAC on the CNS of Mct8KO animals to evaluate its potential as a therapeutic agent. To 
explore if the therapeutic doses of TRIAC used in this study reach the brain and are able to 
exert any function at the genomic level, the expression of T3-dependent genes was studied in 
two different regions of the brain: the cerebral cortex and the striatum. The genes selected for 
this study were the T3-responsive genes (Hernandez et al., 2012) Hr and Cbr2 that are altered 
in Mct8 deficiency (Morte et al., 2010) as well as other genes that, although they are not 
altered in Mct8-deficient mice, they are T3-responsive genes: Itih3, Aldh1a1, and Flywch2 
(Hernandez et al., 2012). 
In the cerebral cortex (Figure 16, left panels) the expression of Hr and Cbr2 was decreased in 
the basal Mct8KO animals compared with the Wt controls, while the expression levels of Itih3, 
Aldh1a1, and Flywch2 did not vary between the basal Wt and the Mct8KO, consistent with 
previous studies (Morte et al., 2010). TRIAC treatment did not increase the expression levels 
of Hr or Cbr2 in the Wt or the Mct8KO animals, suggesting that the treatment is not able to  
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Figure 16. Gene expression analysis of T3-dependent genes in the brain: cerebral cortex (left panel) and 
the striatum (right panel) in Wt and Mct8KO mice in basal conditions and after TRIAC treatment. 
Measurements were obtained by qPCR, and the data are expressed relative to 18S RNA as means ± SE. *p < 
0.05, **p < 0.01, and ***p < 0.001 were determined by two-way ANOVA and Bonferroni’s post hoc test, the 
two factors being genotype and treatment.  
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correct the gene expression defects of the Mct8KO mice. Likewise, TRIAC treatment did not 
increase the expression levels of Itih3 and Aldh1a1 in either the Wt or the Mct8KO animals 
compared with their basal controls. Flywch2 expression did not change after treatment in the 
Wt animals, however, contrary to expectations, TRIAC treatment decreased Flywch2 
expression in the Mct8KO animals compared with untreated controls. 
Outstandingly, in the striatum (Figure 16, right panels) the expression levels of all the selected 
T3-dependent genes were decreased in the TRIAC-treated Mct8KO animals compared with 
their basal controls, although the decrease was only statistically significant for Aldh1a1 and 
Flywch2.  
Subsequently, the ability of TRIAC to reach the brain was evaluated by directly measuring 
TRIAC content in the cerebral cortex and the striatum of Wt and Mct8KO animals. In the 
cerebral cortex, TRIAC content was not increased after treatment either in Wt or Mct8KO 
mice; the small increase in TRIAC content was not statistically significant (Figure 17 A). The 
same was observed in the striatum (Figure 17 B) where TRIAC treatment did not increase 
TRIAC content in either genotype. 
The CNS thyroidal status was further evaluated by determining the T3 content in the cerebral 
cortex and the striatum. In the cerebral cortex (Figure 17 C), the basal T3 content was 
decreased in Mct8KO in comparison to Wt mice, as already described (Dumitrescu et al., 2006, 
Trajkovic et al., 2007). After TRIAC treatment, T3 content decreased in both Wt and Mct8KO 
animals. The same was observed in the striatum (Figure 17 D), although in the Mct8KO mice 
the reduction in the T3 content after treatment was not statistically significant. 
D2 enzymatic activity assays in the cerebral cortex (Figure 17 E) displayed the already 
characterised increase in D2 activity of Mct8KO animals compared with the Wt mice 
(Dumitrescu et al., 2006, Trajkovic et al., 2007) as a compensatory mechanism (Morte et al., 
2010). However, D2 activity in Mct8KO animals did not change after treatment, probably due 
to saturation of its activity. In the Wt animals there was a small increase in D2 activity in the 
cerebral cortex after treatment, although this was not statistically significant. 
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Figure 17. TRIAC and T3 brain content. TRIAC (A) and T3 (C) content in the cerebral cortex and TRIAC 
(B) and T3 (D) content in the striatum in Wt and Mct8KO mice in basal conditions and after TRIAC 
treatment. D2 enzymatic activity in the cerebral cortex of Wt and Mct8KO mice in basal conditions and after 
TRIAC treatment (E). Data are expressed as means ± SE. *p < 0.05, **p < 0.01, and ***p < 0.001 were 
determined by two-way ANOVA and Bonferroni’s post hoc test, the two factors being genotype and 
treatment. 
 
2.2  Gene therapy: Adeno-associated virus 
 
2.2.1 Background 
Gene therapy approaches by the use of adeno-associated virus (AAVs) were performed in 
collaboration with Dr. Samuel Refetoff’s group in the University of Chicago. The findings 
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described in this background section were performed at the University of Chicago and only 
those relevant to the development of this thesis are described below. For complete details see 
Iwayama et al. (2016). 
AAVs are small non-pathogenic virus that can infect various species (Schultz and 
Chamberlain, 2008). In the last years, its use in gene therapy has revealed several advantages 
such as a limited immune response, the ability to infect various cell types including post-
mitotic cells, and persistence without integration into host chromosomes. Adeno-associated 
virus 9 (AAV9) transduces the brain with high efficiency after its delivery into both the blood 
stream and the CSF (Foust et al., 2009, Meyer et al., 2015). Therefore, the goal was to analyse 
if the transfer of human MCT8 (hMCT8) cDNA using AAV9 could correct the brain defects of 
Mct8KO mice. 
AAV9 vectors associated with the short human MCT8 (ShMCT8) protein isoform or an empty 
vector (EV) were injected intravenously (IV; 4x1011 viral particles dose) or 
intracerebroventricularly (ICV; 3x1010 viral particles dose) to P1 Mct8KO and Wt animals. At 
P25, T3 (5 µg T3 /100 g BW) was administered via intraperitoneal injection daily for 4 
consecutive days. At P28, brains were harvested after perfusion to study the effects of the 
delivery of ShMCT8. The following groups were compared: Wt + IV EV injection; Mct8KO + 
IV EV injection; Mct8KO + IV AAV9-ShMCT8 injection and Mct8KO + ICV AAV9-
ShMCT8 injection. 
Whether the ShMCT8 could be successfully delivered to the brain using either IV or ICV 
administration was assessed by western blotting. hMCT8 protein was not detected in EV 
injected animals. The ShMCT8 isoform showed similar amounts of monomers (60 kDa) and 
dimers (120 kDa), however, ICV injection of AAV9-ShMCT8 produced substantially more 
translated protein than IV injection of AAV9-ShMCT8 (Figure 18 A). Therefore, ICV 
delivery provided more hMCT8 protein than IV delivery. 
Next, the functionality of hMCT8 delivery was assessed by determining T3 content in brain 
after 4 days of T3 administration as well as its effects on the expression of the T3-responsive 
gene, Hr. In Mct8KO mice, IV injection of AAV9-ShMCT8 increased brain T3 content 2-fold 
above the background of EV-injected Mct8KO mice while ICV injections of AAV9-ShMCT8 
at did not increase the brain T3 content above background (Figure 18 B). This indicates that 
AAV9-ShMCT8 given IV, but not given ICV, can increase T3 content in cerebral tissue. In 
accordance to this, Hr mRNA expression measured by qPCR revealed that its expression 
increased 2-fold in comparison to the control mice (Mct8KO injected with EV) when the 
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AAV9-ShMCT8 was administered IV, but not ICV (Figure 18 C). Again, AAV9-ShMCT8 
given IV, but not ICV, can increase the expression of the T3-responsive gene Hr. However, 
neither the increase in the T3 content or in the expression of Hr was similar to Wt values. 
 
 
Figure 18. hMCT8 protein in cerebrum of mice injected with AAV9-ShMCT8 or empty vector (EV) 
intravenously (IV) or intracerebroventricularly (ICV). (A) Western blot analysis after SDS-PAGE of 
cerebrum homogenates developed with a hMCT8 antibody using GAPDH as a loading control. B and C show 
the effect of AAV9-ShMCT8 on T3 content (B) and induction of the T3-dependent gene Hr (C) in the 
cerebrum of IV and ICV injected mice. Data are expressed as means ± SE. Statistical differences for Mct8KO 
animals injected with ShMCT8 are compared to the same genotype given EV, ***p < 0.001. (D) Alignment 
of short human MCT8 (shMCT8) and mouse Mct8 (mMct8) along the peptide sequence that recognises the 
hMCT8 antibody. Modified from Iwayama et al., 2016. 
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2.2.2 hMCT8 protein localisation in brain of AAV9-ShMCT8 treated mice 
To explore why delivery of hMCT8 presented some degree of functionality when it was given 
IV while this did not occur when it was delivered ICV, and especially taking into account that 
this last administration route provided more hMCT8 protein, the protein localisation was 
studied by immunohistochemistry. Immunohistological studies were performed at the Instituto 
de Investigaciones Biomédicas in Madrid and are part of this doctoral thesis. 
For this, brains of perfused mice were harvested, sectioned and immunolabeled with a hMCT8 
antibody which partially reacts with mouse Mct8 (Figure 18 D). In the Wt mice injected with 
EV, constitutive Mct8 protein was faintly detected in the cerebral cortex and cerebellum 
(Figure 19 A, B) and it was clearly detected in the choroid plexus (Figure 19 C). This is 
probably due to the partial immunoreactivity of the hMCT8 antibody with mouse Mct8 that 
stains regions with very high expression of the mouse Mct8, such as the choroid plexus. The 
Mct8KO animals injected with EV were labelled to a lesser degree (Figure 19 E, F) than the 
Wt injected with EV. As the Mct8KO mice are generated by deleting exon 3 it is likely that 
they synthesise the amino terminal fraction of the transporter producing a faint staining in 
cerebral cortex and the Purkinje cells of Mct8KO mice when using an antibody directed to the 
amino terminus of the molecule, as it is the case for this study. The positive immunolabelling 
signal detected in the choroid plexus of the Wt (Figure 19 C) was not present in the Mct8KO 
mouse (Figure 19 G), both given EV. 
After delivery of AAV9-ShMCT8 through both IV and ICV administration in Mct8KO mouse, 
the hMCT8 protein was clearly present in the cerebral cortex (Figure 19 I, M), cerebellum 
(Figure 19 J, N), and choroid plexus (Figures 19 K, O). In agreement with results from 
Western blots, ICV injection of ShMCT8 produced greater amounts of the hMCT8 protein in 
cerebral cortex (compare Figures 19 I, M; 20 J,N; 20 K,O), compared to IV injection, and 
this hMCT8 protein appeared as aggregated deposits (Figure 19 M). Both in the IV and ICV 
injected mice, hMCT8 expression was predominantly in the cerebral cortex at the granular and 
infragranular layers of the neocortex and at the CA regions of the hippocampus (Figure 20). 
Subcortical regions presented few immunopositive cells, and dentate gyrus displayed almost 
lack of hMCT8 expression (Figure 20 K, O). Furthermore, the dendritic arborizations of some 
Purkinje cells in the cerebellum of both IV and ICV-injected mice were strongly labelled 
(Figure 19 J, N). The most important finding was the robust expression of hMCT8 in the 
choroid plexus of Mct8KO mice following IV-injected AAV9-ShMCT8 (Figure 19 K).  
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Figure 19. Localisation of the expressed hMCT8 protein in brains of Mct8KO mice given AAV9-
ShMCT8 IV and ICV compared with Wt and Mct8KO animals injected IV with EV. Representative images 
showing hMCT8 expression (in brown) detected with a specific hMCT8 antibody in the somatosensory 
region of the cerebral cortex (A, E, I, M), the cerebellar lobule 4 (B, F, J, N), the choroid plexus (C, G, K, 
O) and the BBB in the cerebellar lobule 4 without hematoxilyn counterstaining (D, H, L, P) of Wt (A–D) 
and Mct8KO (E–H) mice injected with EV, injected with AAV9-ShMCT8 IV (I–L), or ICV (M–P). In 
agreement with Western blots results, hMCT8 was present in larger quantities in the cerebral cortex of mice 
injected with the virus ICV (M) than IV (I). However, much of the immunoreactivity was present in 
aggregates (white arrowheads). Some Purkinje cells (white arrows) were observed in both IV- and ICV-
injected cerebellum (J, N) with outstanding hMCT8 expression at the dendritic arborisations (black 
arrowheads). The control, Wt mice injected with EV, did not show the positive signal of dendritic 
arborisations (B). hMCT8 was abundantly present at the choroid plexus of IV-injected Mct8KO mice (K) and 
only spottily expressed in mice given the virus ICV (O). Positive immunolabelling was detected at the BBB 
of Wt mice injected with EV (D) and this labelling was absent in Mct8KO animals injected with EV (H) or 
ShMCT8 (L, P). Scale bars 50 µm. 
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Figure 20. Panoramic views of the localisation of the expressed hMCT8 protein in brains of Mct8KO 
mice injected with AAV9-ShMCT8 IV and ICV compared with Wt and Mct8KO animals injected IV with 
EV. Sections A – O were taken on the coronal plane at the levels of Bregma 2.10 mm (A, E, I, M); Bregma -
0.22 mm (B, F, J, N) and Bregma -1.46 (C, G, K, O). Cerebellar sections (D, H, L, P) were taken on the 
sagittal plane at the levels of Lateral 1.60 mm. Coordinates have been determined according to Franklin and 
Paxinos (2007). Scale bar 1000 µm. 
 
Notably, the distribution of ShMCT8 after IV delivery was like the endogenous Mct8 observed 
in the Wt mouse (Figure 19 C, K) while ICV-delivered ShMCT8 was minimal and confined to 
a few cells of the choroid plexus (Figure 19 O).  
Big efforts were put into determining whether hMCT8 was delivered to the BBB as well as to 
the choroid plexus. Under these experimental conditions the BBB was positively 
immunolabelled in the Wt animals within structures with low amount of neuropil such as the 
thalamus or the cerebellum (Figure 19 D). In the Mct8KO injected with EV animals the BBB 
did not present immunopositive signal in any region (Figure 19 H) and this was also the case 
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for AAV9-ShMCT8 IV and ICV-injected animals (Figure 19 L, P), suggesting that neither 
administration route led to hMCT8 expression at the BBB. 
Finally, confocal microscopy studies verified that hMCT8 was targeted to the apical membrane 
of epithelial cells of the choroid plexus in IV-injected Mct8KO mice and only to a few cells of 
the choroid plexus in ICV-injected Mct8KO (Figure 21 A, B). Moreover, hMCT8 was targeted 
to the cell membrane of brain cells in both IV and ICV-injected mice (Figure 21 C-F).  
 
Figure 21. Membrane localisation of hMCT8 in Mct8KO mice injected with AAV9-ShMCT8 IV and 
ICV. Representative images showing hMCT8 (in red) and nuclei stained with DAPI (in blue) in the choroid 
plexus (A, B), cerebral cortex (C, D) and CA1 region of the hippocampus (E, F) of Mct8KO mice injected 
with AAV9-ShMCT8 IV (A, C, E) or ICV (B, D, F). hMCT8 was localised at the apical membrane of the 
choroid plexus of IV-injected mice (A) and only in a few cells of ICV injected animals (B). hMCT8 was 
localised in the membranes (white arrows) of cortical and hippocampal brain cells of animals injected either 
IV or ICV (C–F). However, a greater amount of hMCT8 was present in the cytoplasm of animals injected 
ICV. (A, B) Scale bar 20 µm; (C–F) scale bar 10 µm. 
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2.3 Novel strategies for thyroid hormone brain delivery: Intranasal route 
 
2.3.1 Background 
The use of delivery pathways that bypass the BBB has potential benefits for the treatment of 
the neurological condition of MCT8 deficient patients. The nasal cavity provides a direct 
pathway to the brain that can be used to deliver therapeutic agents by intranasal administration 
bypassing the BBB in a non-invasive fashion (Hanson and Frey, 2008). Therapeutics 
administered in the nasal cavity can reach the brain directly through the olfactory (Chen et al., 
1998) or the trigeminal pathways (Thorne et al., 2004) as these pathways connect the nasal 
mucosa and the brain. The goal was to explore the use of intranasal delivery as a potential 
route to administer TH to palliate the hypothyroid conditions of Mct8KO mice in brain without 
worsening the peripheral hyperthyroidism. 
Typically, drug formulations used for intranasal delivery must be highly concentrated as 
usually less than 1% of an administered drug can be nasally transported to the brain. High 
concentrated T3 and T4 formulations were design taking into account the solubility of TH and 
the requirements for intranasal delivery. 
 
2.3.2 Exploratory studies 
In the first place, exploratory studies were designed to quickly evaluate the potential use of the 
intranasal pathway for TH delivery in Mct8KO mice. Note that the number of animals used in 
these studies was not sufficient to obtain statistically significant results (2-5 animals); 
nevertheless the qualitative results were consistent enough to withdraw solid conclusions.  
Initially, treatment with T4 was chosen over treatment with T3 as D2 activity can ensure an 
adequate delivery of T3 to the brain from T4 content. In a first set of experiments, Wt and 
Mct8KO mice were treated daily with T4 by intranasal delivery for a long-term period. After 
treatment, both Wt and Mct8KO mice exhibited a decrease in D2 activity in the cerebral cortex 
and increased expression of the T3-dependent gene Aldh1a1 in the striatum, indicating an 
effect of T4 treatment in the brain (Figure 22 A, B). However, T4 and T3 plasma levels, as 
well as the expression of Dio1 in the liver, were also increased after treatment (Figure 22 C, 
D, E) evidencing that intranasal delivery of T4 reaches the circulation. Subsequently, Wt and 
Mct8KO mice were treated with T4 by intranasal delivery for a short-term period and blood 
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was collected to assess T4 levels after treatment. T4 plasma levels were increased even after a 
short-term treatment (Figure 22 F). 
 
 
Figure 22. Effect of intranasal delivery of T4 to Wt and Mct8KO mice for a long-term period (A – E) or a 
short-term period (F). (A) D2 enzymatic activity in the cerebral cortex and (B) gene expression analysis of 
the T3-dependent gene Aldh1a1 in the striatum of Wt and Mct8KO mice in basal conditions and long-term 
T4 treatment. T4 (C) and T3 (D) plasma levels and gene expression of Dio1 in liver (E) in Wt and Mct8KO 
mice in basal conditions and after long-term T4 treatment. (F) T4 plasma levels in Wt and Mct8KO mice in 
basal conditions and after short-term T4 treatment. As a preliminary test, no statistical analyses were 
performed due to the insufficient number of animals. 
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As mice unlike humans present the T4 transporter Oatp1c1 at the BBB it is not possible to 
differentiate if the effects of T4 treatment observed in the brain were due to direct access of T4 
to the brain or were mediated through T4 from the circulation crossing the BBB. Furthermore, 
as MCT8 deficient subjects present high T3 serum levels, TH reaching the circulation should 
be avoided. 
 
2.3.3 T3-BSA binding assay 
In order to prevent TH from reaching the blood torrent after intranasal administration, the 
possibility of using carriers suitable for intranasal administration and capable of binding TH 
was evaluated. 
Previous studies have shown that intranasal administration of BSA is able to distribute 
throughout mice brain shortly after delivery with only 1.5 – 4 % of the dose reaching the 
systemic circulation (Falcone et al., 2014). BSA is able to bind T3 with a high affinity (Okabe 
et al., 1975), which offers the possibility of using BSA as a carrier to deliver T3 to the brain 
through intranasal delivery without entering the blood stream.  
As the drugs must be highly concentrated in order to be suitable for intranasal administration, 
the appropriate concentration of BSA that is able to bind a high concentrated solution of T3 
was determined by a radioactive T3-BSA binding assay. 
Two different concentrations of T3, one highly concentrated and a T3 replacement dose of 
0.02 µg/µl (Di Cosmo et al., 2009) were incubated along with a known quantity of 125I-T3 in 
presence of different concentrations of BSA: 0.25%, 0.5%, 1%, 1.5%, 2% and 5%. As shown 
in Table 1, the ability of BSA to bind T3 was similar for the high concentrated and the 
replacement dose solution. 1% BSA was already binding 84.1% of the high concentrated T3 
and concentrating BSA up to 5% only increased T3 binding in 6% in comparison to the 
binding achieved by 1% BSA.  
As the experiments assessing the distribution of BSA throughout the brain and the blood 
stream after intranasal administration were performed with 1% BSA (Falcone et al., 2014) and 
taking into account the outcome of the present T3-BSA binding assay, 1% BSA was 
considered the most suitable dose to use as a carrier for intranasal administration of T3. 
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 0.25% BSA 0.5% BSA 1% BSA 1.5% BSA 2% BSA 5% BSA 
High T3 
 
 
70.5% 
 
79.7% 
 
84.1% 
 
87.8% 
 
88.06% 
 
90% 
Replacement T3 
(0.02µg/µl) 
 
ND 
 
79.9% 
 
88.8% 
 
ND 
 
94.7% 
 
97.2% 
 
Table 1. Percentage of two solutions of T3 (one highly concentrated “High T3” and a T3 replacement dose 
“Replacement T3”) bound to different concentrations of bovine serum albumin (BSA). ND = not determined. 
 
2.3.4 Intranasal T3 treatment 
Finally, the ability of T3 to reach the mouse brain circumventing the blood was assessed by 
treating Wt mice with a high concentrated solution of T3 bound to 1%. Furthermore, the 
capacity of the vasoconstrictor PHE (Dhuria et al., 2009) to reduce the passage of the 
administered solution to the circulation was also evaluated. The following groups were 
prepared: Basal Wt; Wt + T3 (Wt treated with T3); Wt + T3-BSA (Wt treated with T3 bound 
to 1% BSA); Wt + T3-BSA-PHE (Wt treated with T3 bound to 1% BSA and PHE 1%). 
Following a short-term intranasal treatment, blood was collected to assess T3 plasma levels. 
T3 determinations in plasma revealed that intranasal treatment with T3 reached the circulation 
as expected and increased T3 plasma levels about 10 times in comparison to the Wt. Intranasal 
delivery of T3 bound to BSA alone or in combination with the vasoconstrictor PHE was not 
able to prevent T3 from reaching the circulation as both treatments increased T3 levels in 
plasma even more than 10-fold the levels of the Wt (Figure 23).  
The use of BSA or the vasoconstrictor PHE does not improve the TH intranasal delivery 
treatment as they do not prevent TH from reaching the blood torrent.  
 
Figure 23. T3 plasma levels in Wt mice after intranasal 
administration of a high concentrated solution of T3 alone 
(Wt + T3), bound to 1% BSA (Wt + T3-BSA) or bound to 
1% BSA and in presence of the vasoconstrictor 
phenylephrine (Wt + T3-BSA-PHE). Data are expressed as 
means ± SE. ***p < 0.001 was determined by One-way 
ANOVA and Bonferroni’s post hoc test. 
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TH play an essential role both in the developing and the adult CNS. Deficit of TH leads to 
neurological abnormalities with different functional consequences depending on the timing and 
the cause for TH deficiency. The developing CNS is particularly sensitive to TH deficiency as 
TH deficit may cause irreversible damage. Understanding the physiological mechanisms that 
underlie T3 availability to the developing brain is essential to get insight into pathological 
conditions.  
In the lasts years our group has focused on a rare disease caused by mutations in the TH 
transporter MCT8 known as the AHDS. Patients present severe neurological impairments 
caused by diffuse brain damage existent from prenatal stages, for which there is presently no 
effective treatment. Knowledge of TH availability and action during brain development will 
help to design therapeutics and timing of treatment for TH related diseases, namely for the 
AHDS.  
The present work has aimed to: (i) explore the physiological mechanisms that ensure 
appropriate levels of T3 during perinatal stages of mouse brain development with special focus 
on the relative contribution of maternal TH and foetal brain D2 activity and (ii) to perform 
preclinical studies in Mct8 deficient mice to explore possible therapies for MCT8 deficient 
patients. 
 
PART I: Contribution of maternal hormones and foetal D2 to thyroid 
hormone brain economy during perinatal development in mice 
The concentrations of the genomically active hormone T3 in the brain depend on TH transport 
across the brain barriers, the local generation of T3 in astrocytes by D2, and TH degradation by 
D3. In addition, circulating foetal TH concentrations derive partly from the mother. How all 
these factors interact to ensure “brain euthyroidism” has not been studied in mice. The 
contribution of maternal TH to embryos has previously been extensively studied in rats, using 
models of combined maternal and foetal hypothyroidism (Calvo et al., 1990, Grijota-Martínez 
et al., 2011). In these studies T4 administration to hypothyroid pregnant dams resulted in an 
increase of foetal T3 brain content along with an increase in the expression of T3-dependent 
genes. On the contrary, T3 administration to hypothyroid pregnant dams did not increase foetal 
T3 brain content and did not induce the expression of T3-dependent genes despite the 
expression of the TH transporter Mct8 at the BBB and even in presence of T3 in foetal plasma 
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and tissues other than the brain. It was therefore proposed that foetal brain is crucially 
dependent on T4.  
Traditionally the rat has been the most commonly used animal model to study the thyroid 
physiology and TH action in brain. However, in the last years the mouse has replaced the rat as 
the most widely employed model due to the growing accessibility to genetically modified mice 
and this is providing new insights about thyroid physiology and pathological events. As 
pointed out above, TH brain availability during mouse brain development has not yet been 
studied. Detailed knowledge of TH availability and economy during mouse embryonic 
development is essential to understand the changes induced by genetic manipulations of 
transporters and deiodinases.  
The aim of the present study was to evaluate the relative contribution of maternal TH and 
foetal brain D2 to TH foetal brain homeostasis in mice by treating euthyroid pregnant dams 
with T4 or T3 from E12 to E18. Due to the difficulties to obtain plasma samples from E18 
foetuses, foetal livers were used assuming that TH content in the liver reflects TH levels in 
plasma.  
 
1.1 Peripheral effect of thyroid hormone treatment in dams and foetuses 
After T3 treatment, T4 decreased in maternal plasma, in all probability caused by TSH 
suppression, and it also decreased in foetal liver. T3 was increased in maternal plasma, but not 
in foetal liver. As maternal T3 treatment has been shown not to suppress foetal TSH (Morreale 
de Escobar et al., 1993, Grijota-Martínez et al., 2011), the decrease in the foetal liver T4 would 
reflect the reduction of circulating maternal T4. In view of this, a fraction of at least 50% of 
total liver T4 in the E18 mouse foetus derives directly from the mother. After T4 treatment, T4 
was accordingly increased in the maternal plasma and also in the foetal liver, confirming that 
exogenously administered T4 to the mothers can cross the placental barrier (Dong et al., 2015). 
In contrast T3, which would be derived from monodeiodination of the administered T4, was 
increased in maternal plasma but again not in foetal liver. These results suggest that the 
exogenously administered T3 and the endogenously produced T3 from the administered T4 to 
the mother had similar distributions in the maternal and foetal compartments. 
Interestingly, even though T4 was increased in the foetal liver after administration to the 
mothers, T3 was not increased, suggesting lack of foetal T4 to T3 conversion in liver or 
elsewhere. Ontogeny studies in rats (Bates et al., 1999) showed that D1 activity and Dio1 
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mRNA were detectable in several foetal tissues at E21, but at very low levels. Low tissue 
activity of D1, together with a high Km for T4 would predict negligible 5’ deiodination of T4. 
This is in agreement with studies in mouse foetal liver with undetectable levels of Dio1 mRNA 
expression (Li et al., 2012) and D1 activity (Ferrara et al., 2013). In the present study, D1 
activity was not detectable in the liver of euthyroid E18 foetuses and, moreover it was not 
responsive to variations in the liver TH content resulting from T3 or T4 treatment to the 
mothers. 
A first conclusion is that a large amount of foetal T4 could be of maternal origin and that 
maternal-foetal T3 transfer is tightly regulated most probably at the placental level. This 
contrasts with findings in rats in which decreased levels of T4 in thyroidectomised mothers did 
not result in decreased T4 content in foetal liver (Grijota-Martínez et al., 2011). These 
discrepancies might be explained by the timing of thyroid gland development and the moment 
in which the determinations were made. In the experiments with rats, determinations were 
made on E21, 4 days after onset of foetal thyroid function. In the current mouse experiments, 
determinations were made at E18, i.e., 1.5 days after onset of foetal thyroid function. Therefore 
the contribution of the foetal thyroid would be larger in the rat experiments than in the present 
studies. As a matter of fact, in the E18 mouse the contribution of maternal T4 can be estimated 
to be above 2/3 of the total foetal liver T4 concentration from the results in figure 6B.  
One of the limitations of the present study is that the levels of TH in foetal plasma are being 
inferred from the TH content detected in the foetal liver. Expression of transporters Lat1 and 
Lat2 was downregulated in the foetal liver after treatment which opens up the possibility that 
foetal TH liver content might not be accurately reflecting the plasma levels. However, taking 
into account that concentration of circulating amino acids is far higher than that of TH, it is 
difficult to make any conclusions about the physiological significance of this downregulation 
on TH transport as it might be reflecting a decrease in the need for amino acids in the liver. 
Moreover, past studies have proven accurate correlations between foetal TH content in 
peripheral tissues like liver and heart with TH levels in plasma (Calvo et al., 1990). 
Furthermore, the main TH transporter in the liver, NTCP, and the Mct8 transporter are not 
differentially regulated in hyperthyroid conditions (Engels et al., 2015), suggesting that TH 
transport to the liver is not impaired under hyperthyroid conditions. 
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1.2 Effects of maternal thyroid hormone treatment in foetal brain 
Regarding the foetal brain, T4 content reflected the peripheral T4 status of the foetus while T3 
content remained constant under a range of T4 concentrations in brain. As for the liver, it 
appears that a fraction of at least 50% of total brain T4 in the E18 mouse foetus derives from 
the mother. In accordance to the stable concentrations of T3 in the foetal brain was the 
expression of the T3-dependent gene Aldh1a1 which was constant despite the variations on the 
T4 brain content. T3 brain homeostasis was not achieved through the regulation of TH-
transporters as the expression of Mct8, Oatp1c1 or Lat2 did not vary in consequence to the 
treatments, that is to say, their expression did not vary under changing concentrations of brain 
T4. The relative expression of these transporters at embryonic stages in comparison to later 
stages in life such as P30 revealed that Mct8 expression is the same at both ages whereas 
Oatp1c1 and Lat2 expression is higher at P30. In accordance with this, Mct8 expression at E18 
was much more abundant than Oatp1c1 and Lat2 expression in foetal brain. This could be 
pointing to the importance of Mct8 during embryonic development although its role still 
remains unknown.  
Another way to achieve brain TH homeostasis is through the regulation of deiodinases. D3 is 
necessary for the regulation of T3 brain content and it is particularly important during 
development (Hernandez et al., 2010, Zoeller, 2010). qPCR results demonstrated that Dio3 
expression levels in the foetal brain were not modified as a result of the different treatments. 
As Dio3 mRNA content and D3 activity are well correlated the results suggest that, under 
these circumstances, D3 is not involved in facilitating an appropriate content of T3 in the foetal 
brain. Expression of Dio3 in neonatal stages of development might be limited to specific 
regions, such as to areas involved in sexual differentiation, to control local T3 concentrations, 
as has been described in rats (Escámez et al., 1999). On the other hand, D2 activity in the 
foetal brain was elevated under reduced T4 content and decreased under elevated T4 brain 
content suggesting that D2 activity plays a critical role in maintaining an appropriate content of 
T3 in the foetal brain. Dio2 mRNA expression analysis revealed no changes at the 
transcriptional level despite the different treatments. Dio2 is regulated at transcriptional level 
by its end product T3, whereas its substrate T4 regulates its activity at post-translational level 
(Burmeister et al., 1997) so the results overall reinforce that brain T3 content is not altered 
despite the different treatments, that the treatments alter T4 brain content and that T3 derived 
from T4 by D2 activity in the brain provides an essential source of T3 during mouse foetal 
development.  
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Detection of Dio2 mRNA expression by in situ hybridization at E15 suggests a role for TH in 
early development before the onset on the foetal thyroid gland, that in the mice is E16.5. Dio2 
mRNA expression greatly increases at E18, the day prior to birth as it has been reported in rat 
activity assays (Ruiz de Oña et al., 1988). At these stages, detection of Dio2 mRNA expression 
at the meninges, the ependymal layer of the lateral ventricles and the choroid plexus suggests 
an important role of D2 at the BCSFB. Dio2 mRNA expression at the meninges is of great 
importance as the primitive meninge is the origin of the vascular plexus that will give rise to 
the brain vasculature (Marin-Padilla, 1985). Dio2 mRNA expression at the ependymal layer of 
the lateral ventricles and the choroid plexus is also highly relevant as at these stages the lateral 
ventricles take up a big surface of the brain and are largely occupied by the choroid plexus 
(O'Rahilly and Müller, 2008) and because the choroid plexus may have a greater transport 
capacity during early stages of brain growth and development (Keep and Jones, 1990).  
So during brain angiogenesis and brain embryonic development, T4 transport across the 
choroid plexus along with D2 activity transforming T4 into T3 at the BCSFB might be key 
events of TH action in brain in contrast to adult stages when T4-to-T3 conversion by D2 is 
mediated mostly in the astrocytes (Guadaño-Ferraz et al., 1997). Furthermore, TH at perinatal 
stages might be regulating key events such as corticogenesis in the meninges (Decimo et al., 
2012) or embryonic neurogenesis in the lateral ventricles (Urban and Guillemot, 2014). 
It is important to point out that the data suggest that, although maternal T4 contributes 
enormously to the total foetal T4 pool, under low levels of maternal T4 the foetus is able to 
compensate for the lack of maternal TH. This is also observed in foetuses coming from 
thyroidectomised rats that did not present alterations in the T3 or T4 brain content, in the 
expression of T3-dependent genes (Grijota-Martínez et al., 2011), or in the brain D2 activity 
(Ruiz de Oña et al., 1988) suggesting an important role of the foetal thyroid gland in rats. In 
the present study, a reduction in the plasma levels of T4 in the mother led to a decrease in T4 
foetal brain content and consequently to an increased D2 activity highlighting important 
regulatory mechanisms in the foetal brain. This might indicate that in absence of maternal TH, 
the foetus can trigger compensatory mechanisms, and conversely, when the foetal gland is not 
functional (e.g. after treatment with antithyroid drugs) maternal TH can compensate for the 
lack of foetal TH. Nevertheless, a previous study demonstrated that administration of T4 to 
mothers increased the expression of T3-dependent genes in the cerebral cortex of E16 foetuses 
(Dong et al., 2015) suggesting that during early developmental stages foetuses might be more 
sensitive to maternal TH. 
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1.3 Role of D2 in Mct8 deficiency during early brain development 
After proving for the first time the important role that D2 plays during mouse brain embryonic 
development in the supply of brain T3, its contribution to perinatal brain development was 
further evaluated by using different KO mice models. The expression of T3-dependent genes 
was analysed as an indicator of the brain TH status under D2 deficiency conditions. The 
contribution of D2 to the TH brain excess characteristic of perinatal Mct8KO mice was also 
evaluated. 
This was done by comparing the expression levels of a set of T3-responsive genes (Hr, Shh 
and Klf9) in Wt, Mct8KO, Dio2KO and double KO Mct8/Dio2KO mice in the cerebral cortex 
at P3. In Mct8KO animals the expression of Hr and Shh was increased in comparison to Wt 
animals. This was indicative of a situation of brain hyperthyroidism in Mct8KO mice as 
already known (Ferrara et al., 2013, Nuñez et al., 2014). Dio2KO animals presented brain 
hypothyroidism with reduced expression of Hr and Shh. Klf9 presented mild increased 
expression in Mct8KO animals and subtle decrease in Dio2KO mice, not statistically 
significant in both cases, indicating that at these stages Klf9 might still not be fully sensitive to 
TH. The hypothyroid brain condition present in Dio2KO mice at P3 did not trigger an increase 
in the expression of the gene encoding for Mct8 as a compensatory mechanism. Brain 
hypothyroidism, with reduced expression of T3-dependent genes during perinatal stages of 
Dio2KO mice contrasts with Dio2KO mice at P15 when the expression of T3-responsive genes 
is not altered (Galton et al., 2007) and reinforces the findings above indicating that D2 plays a 
critical role in the supply of T3 during perinatal brain development.  
Expression of Hr, Shh and Klf9 in the double Mct8/Dio2KO mice was the same as in the single 
Dio2KO indicating that Mct8/Dio2KO animals present a state of brain hypothyroidism. It can 
be concluded that D2 activity is necessary to generate the hyperthyroid state in the brain of 
Mct8KO animals during perinatal stages of development and that TH excess is not due to 
increased TH transport directly from the systemic circulation. During perinatal life Mct8KO 
mice manifest slight hyperthyroxinemia. This could provide a relative excess of substrate to 
the D2, sufficient to increase T3 formation but not to increase D2 degradation. It is clear that 
D2 provides the brain with T3; however, the role of Mct8 transporter at these stages of 
development still remains unknown and it cannot be ruled out that Mct8 mediates T3 efflux 
and/or degradation of T3 by D3, as suggested previously (Nuñez et al., 2014, Stohn et al., 
2016). 
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The fact that the expression of T3-dependent genes in the double Mct8/Dio2KO animals was 
not different from the hypothyroid state present in the single Dio2KO mice suggests that D2 
might be only or most relevant source of brain T3 during perinatal development.  
Altogether the data suggests that during mouse prenatal brain development maternal T4 is an 
essential source of TH. T4 reaches the CSF in the meninges and the lateral ventricles, where 
D2 is present, through the choroid plexus so T3 could be locally formed. Taking into account 
the large surface of the ventricles at these stages, T3 could reach the brain through the 
ventricles and the meninges and access the neural cells by TH transporters to exert its action at 
the genomic level. Dio2 mRNA expression in other brain structures different from the BCSFB, 
such as the striatum, suggests that D2 in the astrocytes may be already generating T3 through 
T4 available from the BBB although probably in a lesser extent than in the adult (Figure 24). 
 
 
Figure 24. Proposed model of T3 availability to the mouse developing brain. T4 mostly of maternal 
origin reaches the brain mainly through the CSF and gets converted into T3 by D2 (in red) at the BCSFB 
(mng, LV, chp). From the CSF the T3 could spread throughout the brain and access the neural cells to exert 
its action. Dio2 mRNA expression at other structures such as the CPu suggests that T4 can also cross the 
BBB and be locally converted into T3 by D2, although probably in a less important fashion than in adult 
mouse. chp, choroid plexus; CFS, cerebrospinal fluid; CPu, caudate putamen (striatum); LV, lateral 
ventricles and mng, meninges. 
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PART II: Therapeutic approaches for MCT8-deficiency treatment 
MCT8 deficient patients present severe mental retardation, impaired ability to speak, 
diminished muscle tone and movement abnormalities. Currently there is no effective treatment 
to improve the neurological impairments of MCT8 deficient patients. Moreover, studies in 
rodents and humans suggest that the neurological defects are compatible with the deficient 
action of T3 in the developing brain caused by impaired TH availability to the target neural 
cells (López-Espíndola et al., 2014) and that the main restriction for T3 entry into the target 
neural cells is at the BBB (Ceballos et al., 2009). For this reason the therapeutic strategies 
developed in this thesis have focused on methods that can either bypass the brain barriers by 
the use of TH analogues that are not transported by Mct8, such as TRIAC, by the use of 
alternative delivery pathways that can circumvent the BBB, such as intranasal administration 
or by replacing MCT8 by the use of AAVs to try to correct brain defects. 
 
2.1 Thyroid hormone analogues: TRIAC 
TRIAC is a TH analogue with many known properties that make it a good candidate for the 
treatment of MCT8 deficiency. However, how therapeutic doses of TRIAC may affect the 
physiology of Mct8KO mice or whether it is able to exert a function at the genomic level in the 
brain, inducing similar neuronal gene responses as T3 in vivo, is not known. Although Mct8KO 
mice do not present gross neurological abnormalities, they faithfully replicate the endocrine 
abnormalities of patients as well as they display alterations in the expression of some T3-
dependent genes that offer the possibility to assess TRIAC action in the brain. Hence, the goal 
was to characterise the effects of therapeutic doses of TRIAC in Wt and Mct8KO mice with 
special focus on the CNS of juvenile mice to ultimately evaluate TRIAC as a possible 
therapeutic agent suitable for patients with MCT8 mutations. 
The treatment consisted on the administration of therapeutic doses of TRIAC (30 ng TRIAC/g 
BW) in the drinking water from P21 to P30 to Wt and Mct8KO littermate mice. Treatment 
greatly increased TRIAC plasma levels in both the Wt and Mct8KO animals similarly, 
suggesting that TRIAC availability and metabolism was not modified in the Mct8KO. TRIAC 
treatment drastically decreased plasma T4 levels in both the Wt- and Mct8KO-treated animals 
evidencing that Mct8 deficiency does not interfere with the inhibition of TSH by TRIAC. T4 
plasma levels in Mct8KO animals after treatment were 6 times lower than those of basal Wt 
animals indicating that therapeutic doses of TRIAC lead to severe hypothyroxinemia, which 
 81 
 
Discussion 
may be potentially harmful unless counteracted by its thyromimetic effect. One of the most 
relevant findings is that TRIAC treatment suppressed the elevated levels of T3 characteristic of 
Mct8 deficient animals, and even decreased it below normal levels. In contrast, it did not affect 
T3 plasma levels of Wt-treated animals. This is of great relevance as, in this respect, TRIAC 
could be a beneficial treatment in ameliorating the peripheral tissue hyperthyroidism present in 
Mct8KO animals. In the treated Wt animals, T3 plasma levels are likely maintained by the 
elevated D1 activity in the liver which is in turn stimulated by TRIAC regardless of the low T4 
plasma levels. In the Mct8KO-treated mice, the further decreased levels of plasma T4 are not 
enough to maintain the high plasma T3 levels characteristic of this genotype despite the 
increase in D1 activity. This observation is consistent with the T4/T3 plasma ratios which are 
similar in the treated Wt and Mct8KO mice being 43.5 and 45.2, respectively.  
It is already known that TRIAC enters the liver after treatment (Medina-Gomez et al., 2008). 
Like T3, TRIAC exerts a direct action in the liver as D1 activity and Dio1 expression increased 
in the Wt and Mct8KO mice after treatment. Therefore, although TRIAC treatment restored the 
plasma T3 levels in Mct8KO animals into the reference range, the liver was still hyperthyroid, 
due to its thyromimetic action. On the other hand, at the dose used in this study, TRIAC did 
not affect the expression of the T3-dependent gene Serca2a in the heart. This is in agreement 
with two other separate studies in rodents, in which similar or even higher doses of TRIAC 
than those used in this study failed to increase Dio1 mRNA abundance and D1 activity in the 
heart, despite clear uptake of TRIAC (Medina-Gomez et al., 2008, Liang et al., 1997) in the 
tissue.  
Because patients suffering from MCT8 deficiency present very severe neurological 
impairments and the therapeutic options currently available have not been successful in 
improving these disorders, the ultimate goal of this study was to determine whether therapeutic 
doses of TRIAC are able to reach the brain and exert a thyromimetic action in the absence of 
Mct8. 
In vitro studies have demonstrated that TRIAC has the ability to induce similar neuronal gene 
responses as T3 (Kersseboom et al., 2015). Unfortunately, the use of the established 
therapeutic doses in vivo failed to reproduce this effect in Mct8KO mice. TRIAC treatment did 
not increase the expression of T3-responsive genes neither in the cerebral cortex nor in the 
striatum and, on the contrary, there was a reduction in the expression of a few T3-dependent 
genes in both cerebral regions after treatment. This suggests that therapeutic doses of TRIAC 
are not sufficient to induce gene expression in the brain, and may aggravate the mild brain 
hypothyroid situation present in Mct8KO mice. This observation was confirmed by the direct 
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measures of TRIAC and T3 content in the cerebral cortex and the striatum of untreated Wt and 
Mct8KO animals and after TRIAC treatment. In the striatum TRIAC content did not increase 
after treatment with TRIAC in the Wt or the Mct8KO animals. In the cerebral cortex there was 
a subtle increase in the content of TRIAC in both Wt and Mct8KO animals after treatment, but 
this increase was not statistically significant. Regarding T3 content, there was a substantial 
decrease after TRIAC treatment in both genotypes on each cerebral region. These two 
observations provide direct evidence to support that this dose of TRIAC is not sufficient to 
increase TRIAC in the brain or to have effects on gene expression in brain cells and that it 
aggravates the hypothyroid state of the brain. 
Because the main source of T3 in the brain is the one provided by the local conversion of T4 
into T3 by D2 (Crantz et al., 1982), most probably the reduction in the T3 content of the brain 
was due to the great decrease in the plasma T4 levels of the treated animals, especially in the 
TRIAC-treated Mct8KO animals. TRIAC treatment did not have an effect on D2 activity in the 
cerebral cortex of either WT or Mct8KO mice in comparison to their basal controls. Other 
studies have already described that similar doses of TRIAC as the one used here do not affect 
D2 cerebral cortex activity in hypothyroid rats (Liang et al., 1997), suggesting that TRIAC 
does not have an effect per se on D2 brain activity.  
It is concluded that treatment with therapeutic doses of 30 ng TRIAC/g BW/day in Mct8KO 
mice restores plasma T3 levels but severely decreases T4 levels. TRIAC treatment increases 
D1 activity and Dio1 gene expression in the liver, but does not have any effect on cardiac T3-
dependent gene expression. While TRIAC has a potential beneficial effect reducing the 
peripheral hyperthyroidism without affecting the heart, it is not able to normalise the 
thyrotoxic effect in the liver characteristic of Mct8 deficiency. Also, although treatment with 
the established therapeutic doses of TRIAC increased 3-fold the TRIAC levels in plasma; these 
were insufficient to increase TRIAC content in the brain and to promote the expression of T3-
dependent genes in brain cells. Furthermore, treatment led to a situation of brain 
hypothyroidism with reduced T3 content. TRIAC treatment would generate a situation of 
severe hypothyroxinemia that could be potentially harmful, especially for the brain, suggesting 
that TRIAC treatment in MCT8 deficiency should be considered with caution. 
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2.2  Gene therapy: Adeno-associated virus 
In the last years the use of AAVs has been increasingly successful in clinical gene therapy both 
for monogenic and complex diseases (Kotterman and Schaffer, 2014) and offers a potential 
treatment for patients suffering from MCT8-deficiency. Among the available AAV vectors, 
AAV9 has been shown to cross the BBB and to transduce wider brain areas and more cell 
types than other AAVs (Foust et al., 2009).  
In this approach we aimed to evaluate the effects of the delivery of the short isoform of human 
MCT8 (ShMCT8) cDNA in the CNS of Mct8KO animals in vivo using AAV9 viral vectors. 
The AAV9-ShMCT8 constructs were administered IV or ICV into P1 Mct8KO mice. 
Interestingly, a significant and critical difference was observed in the functional effects of 
ShMCT8 when it was delivered by ICV as compared to IV injection. Despite the fact that the 
ICV route generated a higher level of transcription and translation of hMCT8, only injection 
through the IV route produced a functional effect, as both T3 brain content and expression of 
the T3-dependent gene, Hr, were increased after daily administration of T3 for 4 days before 
P28 when brains were collected.  
When the delivered hMCT8 was studied at a immunohistochemical level it was observed that 
both IV and ICV injections of AAV9-ShMCT8 produced protein in the membrane of neural 
cells and within neuronal processes such as dendrites in cerebral cortex, hippocampus and 
cerebellum, with the ICV injection producing greater amounts of the hMCT8. The most 
important finding was at the choroid plexus where normal distribution of MCT8 at this 
structure was only achieved by IV administration of the AAV9-ShMCT8. This is of great 
relevance as the choroid plexus and the endothelial cells lining blood vessels mediate the entry 
of TH from blood and CSF into the brain. According to studies in rat, the choroid plexus is 
responsible for 20% of the TH brain content (Chanoine et al., 1992) which is in agreement 
with the magnitude of increase in brain T3 content in the current study. This observation along 
with the fact that neither IV nor ICV injection was able to induce hMCT8 expression at the 
BBB reinforces what it is already stablished: that MCT8 is essential at the BBB to mediate the 
entrance of TH to the brain (Ceballos et al., 2009). In this way, failure of full integration of 
hMCT8 into BBB could explain the partial rescue of T3 uptake in brains of IV injected 
Mct8KO mice compared to Wt controls. 
Therefore, it is a logical conclusion that for gene therapy-delivered MCT8 to provide maximal 
function, the MCT8 must be targeted to the brain barriers as required for T3 entry into brain 
tissue. Additionally, it might be necessary or beneficial for MCT8 to reach the cell membrane 
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for TH transport into nervous system cells, although this is not the limiting step. It is therefore 
necessary to optimise gene isoform, delivery strategies and viral vector in order to achieve 
functional MCT8 within the brain. These are required to properly target MCT8 to the brain 
barriers using an AAV vector and must be critically considered for the development of a 
successful gene therapy for patients with MCT8 deficiency. 
 
2.3 Novel TH delivery routes: Intranasal delivery 
The last approach for the development of an effective treatment to address the neurological 
impairments of MCT8 deficient subjects consisted on the administration of a brain TH 
replacement therapy delivered through the nasal cavity, as this has the potential to bypass the 
BBB and reach the brain (Hanson and Frey, 2008). Intranasal delivery seemed an encouraging 
option as it has been proved successful to deliver insulin in patients with Alzheimer’s disease 
(Craft et al., 2012) or the pituitary adenylate cyclase activating polypeptide to treat a variety of 
disorders including migraines and depression (Amin et al., 2014).  
In order to fine-tune the methodology, a set of exploratory studies were performed in 
preparation for the experimental strategy. First, Wt and Mct8KO animals were treated with a 
highly concentrated solution of the prohormone T4 through intranasal delivery for a long-term 
period. This treatment had functional effects in the brain decreasing D2 activity in the cerebral 
cortex and increasing the expression of the T3-dependent gene Aldh1a1 in the striatum of both 
Wt and Mct8KO animals. However, this treatment greatly increased T4 and in consequence T3 
plasma levels in both Wt and Mct8KO animals in comparison to their basal controls. T4 
plasma levels also increased after intranasal administration of T4 for a short-term period. From 
these exploratory studies it can be concluded that intranasal delivery of TH enters the blood 
torrent and therefore failed to identify if the TH mediated effects observed in the brain after T4 
treatment were due to T4 reaching the brain directly after intranasal delivery or to the T4 
reaching the brain from the systemic circulation as Mct8KO mice present the T4 transporter 
Oatp1c1 at the BBB. Additionally, in Mct8-deficiency, where the plasma levels of T3 are 
elevated, an increase in the plasma TH levels could be detrimental. For these reasons the focus 
was set on preventing TH from reaching the blood after intranasal delivery. 
BSA has been suggested to work as a carrier for delivering drugs intranasally as it distributes 
throughout the whole brain and it does not reach the systemic circulation (Falcone et al., 2014). 
Taking advantage of the fact that BSA binds T3 with high affinity, the strategy was to 
administer T3 bound to BSA aiming to reach the brain without entering the blood. First, the 
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appropriate concentration of BSA that is able to bind the highest concentration of T3 suitable 
for intranasal delivery was estimated by a carefully designed radioactive BSA-T3 binding 
assay. Then, Wt mice were treated either with T3 alone, bound to BSA or T3 bound to BSA in 
the presence of the vasoconstrictor PHE. Neither the biding of T3 to the BSA nor the use of the 
vasoconstrictor were able to prevent or even reduce the T3 reaching the systemic circulation 
that increased around 10 times the basal T3 plasma levels. 
Despite these initial discouraging findings, intranasal delivery offers so many advantages such 
as the potential to reach the brain bypassing the BBB in a non-invasive manner that it is 
deserving of further investigation to treat MCT8-deficiency neurological symptoms. The most 
immediate goal is to resolve whether TH administered intranasally is able to reach the brain 
directly. To achieve this T3 or T4 should be administered in animals deficient for their specific 
transporters, in other words, either Mct8KO mice should be treated with T3 or Oatp1c1 
deficient mice should be treated with T4. In the absence of TH transporters, TH reaching the 
blood torrent might be prevented and even if it does reach the systemic circulations, the 
potential TH-mediated effects in the brain should be solely related to TH reaching the brain 
directly. To rule out the possibility that even in the absence of the specific transporter the 
administered TH is able to cross the BBB, a dosage of TH that produces an increase in the TH 
plasma levels comparable to that resulting from intranasal administration should be injected 
intraperitoneally and run in parallel as a control.  
The outcome of this study highlights the difficulties of developing an effective treatment for 
MCT8 deficient patients. The coexistence of TH deficiency in the brain and TH excess in 
peripheral tissues means that the treatment should be effective in normalising the thyroidal 
status in the brain without worsening the peripheral hyperthyroidism.   
 
III: Implications of the study and future directions 
Considering the severe defects that MCT8 deficient patients present even before birth (López-
Espíndola et al., 2014), an early diagnosis is essential to prevent unnecessary testing, to offer 
the affected families genetic counselling and most importantly to start with prospective 
treatments as soon as possible.  
The study of TH economy during mouse foetal development will allow the understanding of 
physiological events regarding TH availability and action in brain and, in extent, will provide 
information about TH related pathological conditions. This will permit the development of 
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appropriate treatments and stablish timings to prevent, restore or at least palliate possible 
impairments. As studies with human samples are limited, it is necessary to research in animal 
models to understand TH action during brain development, as accomplished in the present 
work.  
The possibility to perform in utero prenatal diagnosis of MCT8 (Ramos et al., 2011) offers the 
opportunity to start treatments during pregnancy by treating the mothers or by intra-uterine 
administration. Conceivably, TH analogues like DITPA or TRIAC, that have not been 
successful for improving the neurological defects of MCT8 deficient patients in postnatal 
stages, may be effective when administered in early stages of development. For instance, 
DITPA has been shown, in rodents, to cross the placental barrier and to normalise TSH levels 
and exert thyromimetic actions on the expression of T3-dependent genes in the pups’ brain 
(Ferrara et al., 2014), although its use still has not been approved for pregnant women. 
Transplacental passage of TRIAC has been documented in pregnant women, as a possible 
therapy for foetal hypothyroidism, with no adverse reactions (Cortelazzi et al., 1999). 
However, the effects of TRIAC during Mct8 deficiency foetal development have not yet been 
assessed.  
In humans, during the 13-20th week postmenstrual age of gestation there is D2 activity which 
leads to an accumulation of T3 in the cerebral cortex that follows an increase in the levels of 
T4 in the serum and in the T4 content of the cerebral cortex (Kester et al., 2004). Therefore, 
treating mothers carrying MCT8 deficient foetuses with LT4 or the TH analogue TETRAC, 
which can be metabolised into T3 and TRIAC respectively by D2 activity, might be 
appropriate. This thesis has proven that D2 activity is critical to provide T3 during mouse brain 
development, making the mouse a suitable experimental model to test these possibilities. 
Finally, the findings regarding TRIAC treatment to Mct8KO mice can have a direct impact on 
the patients as TRIAC has been administered since 2014 to MCT8 deficient patients, some of 
them as part of a clinical trial that is testing TRIAC treatment in MCT8 deficiency (Iglesias et 
al., 2016, Groeneweg et al., 2016). So far the outcome of this treatment has revealed similar 
results to those obtained in Mct8KO mice in this thesis: a strong reduction in the circulating 
levels of T3 and T4 and also a slight improvement of peripheral markers. While lowering 
peripheral T3 levels is clearly beneficial for the patients, the extent of the consequences that 
might arise from low T4 serum levels is not known. Low T4 plasma levels might have a more 
detrimental effect in the brain of Mct8KO mice than in MCT8 deficient patients, as in the latter 
both T3 and T4 entry to the brain is believed to be impeded, nevertheless, the potential 
consequences of low T4 serum levels in humans should not be ignored. 
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CONCLUSIONS 
 
1. In the mouse, at least 50% of foetal T4 during late gestation is of maternal origin and 
maternal-foetal T3 transfer is tightly regulated, most probably at the placental level. 
 
2. Regulation of transporter (Mct8, Oatp1c1, Lat2) or Dio3 expression does not appear to 
play a role in maintaining foetal brain T3 homeostasis under a range of brain T4 
values. 
 
3. D2 activity is already present at E18 and is highly regulated at the post-translational 
level under changing T4 content in the brain. Conversion of T4 into T3 by D2 activity 
might be the only source of T3 during mouse brain development. 
 
4. Dio2 mRNA is expressed in the mouse brain at least from E15. Its expression in the 
meninges, the ependymal layer of the lateral ventricles and the choroid plexus suggests 
an important role of D2 at the BCSFB highlighting its relevance as a source of TH 
during early brain development. T4 transport across the choroid plexus along with D2 
activity at the BCSFB might be key events in TH action in brain during embryonic 
development. 
 
5. Despite the significant maternal T4 contribution to the total foetal T4 pool, under low 
levels of maternal T4 the foetus is able to trigger compensatory mechanisms in the 
brain to ensure an appropriate content of T3. 
 
6. D2 activity is required to generate the TH excess in the brain of Mct8KO animals 
during perinatal stages of development and this hyperthyroidism is not due to increased 
TH transport directly from the systemic circulation. 
 
7. Therapeutic doses of TRIAC in Mct8KO mice restore plasma T3 levels but severely 
decrease T4 levels which lead to a state of brain hypothyroidism with reduced T3 
content. An increase in the plasma TRIAC levels after treatment is not sufficient to 
increase TRIAC levels in the brain and to promote the expression of T3-dependent 
genes in brain cells. 
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8. MCT8 delivery by AAV9 to the choroid plexus by IV but not ICV injection is crucial 
for its proper function by increasing T3 content. MCT8 mediates the entrance of T3 in 
the brain. The correct delivery route along with the appropriate AAV vector that 
restores MCT8 at the brain barriers are critical processes for an effective gene therapy 
to provide functional MCT8 in the brain of MCT8 deficient patients. 
 
9. Administration of TH through intranasal delivery is probably not a treatment option 
because it results in increased TH levels in the systemic circulation even when it is 
administered bound to BSA and in the presence of a vasoconstrictor. 
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CONCLUSIONES 
 
1. En el ratón, al menos un 50% de la T4 fetal durante las últimas etapas de la gestación 
es de origen materno y la transferencia materno-fetal de T3 está estrictamente regulada, 
probablemente a nivel placentario. 
 
2. La regulación de la expresión de transportadores (Mct8, Oatp1c1, Lat2) o de la 
desyodasa Dio3 no parece desempeñar una función en el mantenimiento de la 
homeostasis de T3 en el cerebro fetal, en presencia de valores variables de T4. 
 
3. La actividad de la D2 está ya presente a E18 y se regula altamente a nivel 
postraducccional en presencia de valores variables de T4 en el cerebro. La conversión 
de T4 a T3 mediante la actividad de la D2 podría ser la única fuente de T3 durante el 
desarrollo fetal del cerebro de ratón. 
 
4. El mARN de Dio2 está presente en el cerebro de ratón por lo menos desde E15. La 
expresión de Dio2 mARN en las meninges, la capa ependimaria de los ventrículos 
laterales y el plexo coroideo sugieren una importante función de la D2 en la barrera 
sangre-líquido cefalorraquídeo lo que destaca su relevancia como fuente de HT durante 
el desarrollo temprano del cerebro. El transporte de T4 a través del plexo coroideo 
junto con la actividad de D2 en la barrera sangre-líquido cefalorraquídeo podrían ser 
eventos claves en la acción de la HT durante el desarrollo fetal del cerebro. 
 
5. A pesar de la considerable contribución de la T4 materna al conjunto total de T4 fetal, 
en condiciones de bajos niveles maternos de T4 el feto es capaz de activar mecanismos 
compensatorios en el cerebro para asegurar un contenido adecuado de T3. 
 
6. La actividad de D2 es necesaria para generar el exceso de HT en el cerebro de ratones 
deficientes de Mct8 durante etapas perinatales del desarrollo y este hipertiroidismo no 
se debe a un aumento del transporte directo de HT desde la circulación sistémica. 
 
7. Dosis terapéuticas de TRIAC administradas a ratones deficientes de Mct8 restablecen 
los niveles plasmáticos de T3 pero reducen drásticamente los niveles de T4 lo que 
genera un estado de hipotiroidismo cerebral con bajo contenido de T3. El aumento en 
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los niveles plasmáticos de TRIAC tras el tratamiento no es suficiente para aumentar los 
niveles de TRIAC en cerebro e inducir la expresión de genes dependientes de T3 en 
células cerebrales. 
 
8. La localización de MCT8 en el plexo coroideo tras la inyección de AAV9 por vía 
intravenosa pero no por vía intracerebroventricular en cerebros deficientes del 
transportador facilita la entrada de T3 al cerebro. Una correcta vía de administración 
junto con un vector AAV adecuado son procesos críticos para restablecer MCT8 en las 
barreras cerebrales y para logar una terapia génica efectiva que proporcionen un MCT8 
funcional en el cerebro de pacientes deficientes de MCT8. 
 
9. La administración de HT mediante vía intranasal probablemente no sea una buena 
opción para el tratamiento de la deficiencia de MCT8 ya que genera un aumento en los 
niveles circulantes de HT incluso cuando es administrada unida a BSA y en presencia 
de un vasoconstrictor. 
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